# Ecolab Inc.: Form 10-K for the period ended Dec 31, 2021

- Company: [Ecolab Inc.](/companies/ecl.md) (CIK 31462)
- Form: 10-K
- Filed: 2022-02-25
- Accepted by EDGAR: Feb 25, 2022, 08:35 ET
- Period: 2021-12-31
- Accession: 0001558370-22-002059
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/31462/000155837022002059/ecl-20211231x10k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/31462/000155837022002059/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-10-01 to 2021-12-31 | $3.36bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | $12.73bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-10-01 to 2021-12-31 | $2.04bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months, 2021-01-01 to 2021-12-31 | $7.62bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months, 2021-01-01 to 2021-12-31 | $186.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-10-01 to 2021-12-31 | $867.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months, 2021-01-01 to 2021-12-31 | $3.42bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-10-01 to 2021-12-31 | $387.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | $1.60bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2021-01-01 to 2021-12-31 | $230.6m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-10-01 to 2021-12-31 | $44.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | $270.2m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2021-10-01 to 2021-12-31 | $1.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | $3.91 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-10-01 to 2021-12-31 | $1.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | $3.95 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-10-01 to 2021-12-31 | 289,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months, 2021-01-01 to 2021-12-31 | 289,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | $2.06bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | $643.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2021-01-01 to 2021-12-31 | $566.4m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months, 2021-01-01 to 2021-12-31 | $106.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-12-31 | $359.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-12-31 | $4.69bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-12-31 | $21.21bn | us-gaap:Assets |
| Current liabilities | at 2021-12-31 | $3.55bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-12-31 | $13.95bn | us-gaap:Liabilities |
| Current portion of debt | at 2021-12-31 | $411.0m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2021-12-31 | $7.22bn | us-gaap:StockholdersEquity |

## Business

As filed, 76,823 characters.

### General Development of Business.

Ecolab was incorporated as a Delaware corporation in 1924. Our fiscal year is the calendar year ending December 31. International subsidiaries are included in the consolidated financial statements on the basis of their U.S. GAAP (accounting principles generally accepted in the United States of America) November 30 fiscal year ends to facilitate the timely inclusion of such entities in our consolidated financial reporting.

On June 3, 2020, we completed the previously announced separation of our Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX business, followed immediately by the merger (the “Merger”) of ChampionX with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

As discussed in Note 5 Discontinued Operations, the ChampionX business met the criteria to be reported as discontinued operations because the separation of ChampionX was a strategic shift in business that had a major effect on our operations and financial results. Therefore, we reported the historical results of ChampionX, including the results of operations and cash flows as discontinued operations, and related assets and liabilities were retrospectively reclassified for all periods presented herein. Unless otherwise noted, the accompanying financial information has been revised to reflect the effect of the separation of ChampionX and prior year balances have been revised accordingly to reflect continuing operations only.

Subsequent to the separation of ChampionX, we no longer report the Upstream Energy segment, which previously held the ChampionX business. We are aligned into three reportable segments and Other.

Effective in the first quarter of 2020, and in anticipation of the separation of the Upstream Energy business, we created the Upstream and Downstream operating segments from the Global Energy operating segment, which was also a reportable segment. We eliminated the Global Energy reportable segment and created the Downstream operating segment and the Upstream operating segment, which are reported in the Global Industrial reportable segment and newly established Upstream Energy reportable segment which is reported in discontinued operations, respectively. Also, in the first quarter of 2020, we announced leadership changes which allow for shared oversight and focus on the Healthcare and Life Sciences operating segments and established the Global Healthcare & Life Sciences reportable segment. This segment is comprised of the Healthcare operating segment which was previously aggregated in the Global Institutional reportable segment and the Life Sciences operating segment which was previously aggregated in the Global Industrial reportable segment. Additionally, the Textile Care operating segment is reported in Other, which had previously been aggregated in the Global Industrial reportable segment. We also renamed the Global Institutional reportable segment to the Global Institutional & Specialty reportable segment. We made other immaterial changes, including the movement of certain customers and cost allocations between reportable segments.

On December 1, 2021, we acquired Purolite for total consideration of $3.7 billion in cash. Purolite is a leading and fast-growing global provider of high-end ion exchange resins for the separation and purification of solutions that is highly complementary to our current offering and critical to safe, high quality drug production and biopharma product purification in the life sciences industries. It also provides purification and separation solutions for critical industrial markets like microelectronics, nuclear power and food and beverage. Headquartered in King of Prussia, Pennsylvania, Purolite operates in more than 30 countries. Purolite is reported within our Life Sciences operating segment.

We continued to invest in and build our business through various acquisitions that complement our strategic vision. See Part II, Item 8, Note 4 of this Form 10-K for additional information about acquisitions and divestitures.

### Narrative Description of Business.

### General

With 2021 sales of $12.7 billion, we are a global leader in water, hygiene and infection prevention solutions and services. We deliver comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use, and improve operational efficiencies and sustainability for customers in the food, healthcare, hospitality and industrial markets in more than 170 countries around the world. Our cleaning and sanitizing programs and products and pest elimination services support customers in the foodservice, food and beverage processing, hospitality, healthcare, government and education, retail, textile care and commercial facilities management sectors. Our products and technologies are also used in water treatment, pollution control, energy conservation, refining, primary metals manufacturing, papermaking, mining and other industrial processes.

We pursue a “Circle the Customer – Circle the Globe” strategy by providing an array of innovative programs, products and services designed to meet the specific operational and sustainability needs of our customers throughout the world. Through this strategy and our varied product and service mix, one customer may utilize the offerings of several of our operating segments. Important in our business proposition for customers is our ability to produce improved results while reducing their water and energy use. With that in mind, we focus on continually innovating to optimize both our own operations and the solutions we provide to customers, aligning with our corporate strategy to address some of the world’s most pressing and complex sustainability challenges such as water scarcity and climate change. The work we do matters, and the way we do it matters to our employees, customers, investors and the communities in which we and our customers operate.

Sustainability is core to our business strategy. We deliver sustainable solutions that help companies around the world achieve their business goals while reducing environmental impacts. We partner with customers at approximately three million customer locations around the world to reduce water and energy use as well as greenhouse gas emissions through our high-efficiency solutions. By partnering with our customers to help them do more with less through the use of our innovative and differentiated solutions, we aim to help our customers conserve more than 300 billion gallons of water annually by 2030. In 2020, we helped our customers conserve more than 206 billion gallons of water and avoid more than 3.5 million metric tons of greenhouse gas emissions.

The following description of our business is based upon our reportable segments as reported in our consolidated financial statements for the year ended December 31, 2021, which are located in Item 8 of Part II of this Form 10-K. Operating segments that share similar economic characteristics and future prospects, nature of the products and production processes, end-use markets, channels of distribution and regulatory environment have been aggregated into three reportable segments: Global Industrial, Global Institutional & Specialty and Global Healthcare & Life Sciences. Operating segments that were not aggregated and do not exceed the quantitative criteria to be separately reported have been combined into Other. We provide similar information for Other as compared to our three reportable segments as we consider the information regarding its underlying operating segments as useful in understanding our consolidated results.

### Global Industrial

This reportable segment consists of the Water, Food & Beverage, Downstream and Paper operating segments, which provide water treatment and process applications, and cleaning and sanitizing solutions, primarily to large industrial customers within the manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, global refining, petrochemical, pulp and paper industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the four operating segments which comprise our Global Industrial reportable segment follow below.

### Water

Water serves customers across industrial and institutional markets. Within Water, our light industry markets include food and beverage, manufacturing and transportation, institutional clients including commercial buildings, hospitals, universities and hotels, and global high technology serving customers including data centers and microelectronics. Heavy industries served include power, chemicals and primary metals and mining.

Water provides water treatment products and technology programs for cooling water, waste water, boiler water and process water applications. Our cooling water treatment programs are designed to control challenges associated with cooling water systems — corrosion, scale and microbial fouling and contamination — in open recirculating, once-through and closed systems. Our wastewater products and programs focus on improving overall plant economics, addressing compliance issues, optimizing equipment efficiency and improving operator capabilities and effectiveness. We provide integrated chemical and digitally-based solutions, process improvements and mechanical component modifications to optimize boiler performance and control corrosion and scale build-up. Our programs assist in more effectively managing water use for plant processes by optimizing the performance of treatment chemicals and equipment in order to minimize costs and maximize returns on investment.

Our offerings include specialty products such as scale and corrosion inhibitors, antifoulants, pre-treatment solutions, membrane treatments, coagulants and flocculants, and anti-foamers, as well as our 3D TRASARTM technologies, which combines chemistry, remote services and monitoring and control. We provide products and programs for water treatment and process applications aimed at combining environmental benefits with economic gains for our customers. Typically, water savings, energy savings and operating efficiency are among our primary sources of value creation for our customers, with product quality and production enhancement improvements also providing key differentiating features for many of our offerings. Our offerings are sold primarily by our corporate account and field sales employees.

We believe we are one of the leading global suppliers of products and programs for chemical applications within the industrial water treatment industry.

### Food & Beverage

Food & Beverage provides cleaning and sanitation products and programs to facilitate the processing of products for human consumption. Food & Beverage provides detergents, cleaners, sanitizers, lubricants and animal health products, as well as cleaning systems, digitally-based dispensers, monitors and chemical injectors for the application of chemical products, primarily to dairy plants; dairy, swine and poultry farms; breweries and soft-drink bottling plants as well as meat, poultry and other food processors. Food & Beverage is also a leading developer and marketer of antimicrobial products used in direct contact with meat, poultry, seafood and produce during processing in order to reduce microbial contamination. Food & Beverage also designs, engineers and installs CIP (“clean-in-place”) process control systems and facility cleaning systems for its customer base. Water savings, energy savings, and operating efficiency are among our sources of value creation for our customers. Products for use in processing facilities are sold primarily by our corporate account and field sales employees, while products for use on farms are sold through dealers and independent, third-party distributors.

We believe we are one of the leading global suppliers of cleaning and sanitizing products to the dairy plant, dairy, swine and poultry farm, beverage/brewery, food, meat and poultry, and beverage/brewery processing industries.

### Downstream

Downstream provides products and programs for process and water treatment applications specific to the petroleum refining and fuels industry, enabling our customers to profitably refine and upgrade hydrocarbons. We solve our customers’ toughest process and water challenges so they can reliably, sustainably and profitably refine fuels and process petrochemicals. Our proven chemistry and digital technologies combined with service increase refinery and petrochemical plant reliability and the useful life of customer assets while improving product quality and yields. Our product portfolio includes corrosion inhibitors, antifoulants, hydrogen sulfide removal, cold flow improvers, lubricity inhibitors, crude desalting, reactive monomer inhibitors, olefins, anti-polymerants, anti-oxidants and water treatment.

Our customers include many of the largest publicly traded oil, refining and petrochemical companies, as well as national refining and petrochemical companies, and large independent refining companies. Our downstream offerings are sold primarily by our corporate account and field sales employees and, to a lesser extent, through engineering, procurement, and construction contractors (EPC), technology licensors, distributors, sales agents and joint ventures.

We believe we are one of the leading global providers of products and programs for specialty chemical applications to downstream refineries and petrochemical operations.

### Paper

Paper provides water and process applications for the pulp and paper industries, offering a comprehensive portfolio of programs that are used in all principal steps of the papermaking process and across all grades of paper, including graphic grades, board and packaging, and tissue and towel. While Paper provides its customers similar types of products and programs for water treatment and wastewater treatment as those offered by Water, Paper also offers two specialty programs that differentiate its offerings from Water—pulp applications and paper applications. Our pulp applications maximize process efficiency and increase pulp cleanliness and brightness in bleaching operations, as well as predict and monitor scaling potential utilizing on-line monitoring to design effective treatment programs and avoid costly failures. Our paper process applications focus on improving our customers’ operational efficiency, in part through water savings, energy savings and operating efficiency. Advanced digital sensing, monitoring and automation combine with innovative chemistries and detailed process knowledge to provide a broad range of customer solutions. Specialty products include flocculants, coagulants, dewatering aids and digester yield additives. Our offerings are sold primarily by our corporate account and field sales employees.

We believe we are one of the leading global suppliers of water treatment products and process aids to the pulp and papermaking industry.

### Global Institutional & Specialty

This reportable segment consists of the Institutional and Specialty operating segments, which provide specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, government, education and retail industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the two operating segments which comprise our Global Institutional & Specialty reportable segment follow below.

### Institutional

Institutional sells specialized cleaners and sanitizers for washing dishes, glassware, flatware, foodservice utensils and kitchen equipment (“warewashing”), plus specialized cleaners for various applications throughout food service operations, on-premise laundries (typically used by hotel and healthcare customers) and general housekeeping functions. We also sell food safety products and equipment, water filters, dishwasher racks and related kitchen sundries to the foodservice, lodging, educational and healthcare industries. Institutional also provides pool and spa treatment programs for hospitality and other commercial customers, as well as a broad range of janitorial cleaning and floor care products and programs to customers in hospitality, healthcare and commercial facilities. Institutional develops various digital monitoring and chemical dispensing systems which are used by our customers to efficiently and safely dispense our cleaners and sanitizers, and through these products, systems and our on-site sales and service expertise, develop better results for our customers including water savings, energy savings and operating efficiency. In addition, Institutional markets a lease program comprised of energy-efficient dishwashing machines, detergents, rinse additives and sanitizers, including full machine maintenance. Through our EcoSure Food Safety Management business, Institutional also provides customized on-site evaluations, training and quality assurance services to foodservice operations. With the Lobster Ink business, Institutional provides our customers with end-to-end digital training solutions designed to drive corrective actions and optimal frontline execution.

Institutional sells its products and programs primarily through its direct field sales and corporate account sales personnel. Corporate account sales personnel establish relationships and negotiate contracts with larger multi-unit or “chain” customers. We also utilize independent, third-party foodservice, broad-line and janitorial distributors to provide logistics to end customers that prefer to work through these distributors. Many of these distributors also participate in marketing our product and service offerings to the end customers. Through our field sales personnel, we generally provide the same customer support to end-use customers supplied by these distributors as we do to direct customers.

We believe we are one of the leading global suppliers of warewashing and laundry products and programs to the food service, hospitality and lodging markets.

### Specialty

Specialty supplies cleaning and sanitizing chemical products and related items primarily to regional, national and international quick service restaurant (“QSR”) chains and food retailers (i.e., supermarkets and grocery stores). Its products include specialty and general purpose hard surface cleaners, degreasers, sanitizers, polishes, hand care products and assorted cleaning tools and equipment which are primarily sold under the “Ecolab” and “Kay” brand names. Specialty’s cleaning and sanitation programs are customized to meet the needs of the market segments it serves and are designed to provide highly effective cleaning performance, promote food safety, reduce labor, water and energy costs and enhance user and guest safety. A number of dispensing options are available for products in the core product range. Specialty supports its product sales with training programs and technical support designed to meet the special needs of its customers.

Both Specialty’s QSR business and its food retail business utilize their corporate account sales force which manages relationships with customers at the corporate and regional office levels (and, in the QSR market segment, at the franchisee level) and their field sales force which provides program support at the individual restaurant or store level. QSR customers are primarily supplied through third party distributors while most food retail customers utilize their own distribution networks. While Specialty’s customer base has broadened significantly over the years, Specialty’s business remains largely dependent upon a limited number of major QSR chains and franchisees and large food retail customers.

We believe we are one of the leading suppliers of cleaning and sanitizing products to the global QSR market and a leading supplier of cleaning and sanitizing products to the global food retail market.

### Global Healthcare & Life Sciences

This reportable segment consists of the Healthcare and Life Sciences operating segments, which provide specialized cleaning and sanitizing products to the healthcare, personal care and pharmaceutical industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the two operating segments which comprise our Global Healthcare & Life Sciences reportable segment follow below.

### Healthcare

Healthcare provides infection prevention and surgical solutions to acute care hospitals, surgery centers and medical device Original Equipment Manufacturers (“OEM”). Healthcare’s proprietary infection prevention and surgical solutions (hand hygiene, hard surface disinfection, digital monitoring systems, instrument cleaning, patient drapes, equipment drapes and surgical fluid warming and cooling systems) are sold primarily under the "Ecolab," "Microtek," and “Anios” brand names to various departments within the acute care environment (Infection Control, Environmental Services, Central Sterile and Operating Room). Healthcare sells its products and programs principally through its field sales personnel and corporate account personnel but also sells through healthcare distributors.

We believe we are one of the leading suppliers of infection prevention and surgical solutions in the United States and Europe.

### Life Sciences

Life Sciences provides end-to-end cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. These products are primarily sold under the “Ecolab” brand name, and include detergents, cleaners, sanitizers, disinfectants, surface wipes, as well as cleaning systems, electronic dispensers and chemical injectors for the application of chemical products. With the acquisition of Purolite, the portfolio now includes premium fluid treatment and purification solutions with a broad range of unique products sold under the “Purolite” brand name, particularly focusing on biopharma purification solutions, active pharmaceutical ingredients (“API’s”) and high value industrial applications. The Life Sciences portfolio also includes decontamination systems and services utilizing hydrogen peroxide vapor, which are sold under the “Bioquell” brand name. The pharmaceutical clean room environment is the primary area that Ecolab and Bioquell products are utilized. Purolite products are primarily used in the purification of biologic therapeutics, API’s and high value industrial applications. Products and programs are sold primarily through our field sales and corporate account personnel, and to a lesser extent through distributors.

Life Sciences is comprised of customers and accounts related to manufacturing in the following industries: pharmaceutical, animal health and medicine, blood purification and dialysis, biologic products, cosmetics and medical devices. Our tailored, comprehensive solutions and technical know-how focus on ensuring product quality, safety and compliance standards are met while improving operational efficiency in customers’ cleaning, sanitation and disinfection processes. We believe we are one of the leading suppliers of process purification solutions in Europe and North America and of contamination control solutions in Europe, with a growing presence in North America and other regions.

### Other

Other consists of the Pest Elimination, Textile Care and Colloidal Technologies Group operating segments. These operating segments do not meet the quantitative criteria to be separately reported. We disclose these operating segments within Other as we consider the information useful in understanding our consolidated results.

### Pest Elimination

Pest Elimination provides services designed to detect, eliminate and prevent pests, such as rodents and insects, in restaurants, food and beverage processors, educational and healthcare facilities, hotels, quick service restaurant and grocery operations and other institutional and commercial customers. The services of Pest Elimination are sold and performed by our field sales and service personnel.

In addition to the United States, which constitutes the largest operation, we operate in various countries in Asia Pacific, Greater China, Western Europe, Latin America and South Africa.

We believe Pest Elimination is a leading supplier of pest elimination programs to the commercial, hospitality and institutional markets in the geographies it serves.

### Textile Care

Textile Care provides products and services that manage the entire wash process through custom designed programs, premium products, dispensing equipment, water and energy management and reduction, and real time data management for large scale, complex commercial laundry operations including uniform rental, hospitality, linen rental and healthcare laundries. Textile Care’s programs are designed to meet our customers’ needs for exceptional cleaning, while extending the useful life of linen and reducing our customers’ overall operating costs. Products and programs are marketed primarily through our field sales employees and, to a lesser extent, through distributors. We believe we are one of the leading global suppliers in the laundry markets in which we compete.

### Colloidal Technologies Group

The Colloidal Technologies Group (“CTG”) produces and sells colloidal silica, which is comprised of nano-sized particles of silica in water. These products and associated programs are used primarily for binding and polishing applications. CTG serves customers across various industries, including semiconductor manufacturing, catalyst manufacturing, chemicals and aerospace component manufacturing.

CTG incorporates strong collaboration with customers to develop customized solutions that meet the technical demands of their operations. Our silica-based applications are widely used for polishing of silicon wafers, semiconductor substrates and the precision surface finishing of optics, watch crystals and other glass components. We offer a variety of silica-based particles that can be used as binders in heterogeneous catalyst systems and as silica nutrients for manufacturing specialty zeolites. Our silica products are used worldwide as a binder for precision investment casting slurries, which ultimately facilitate the manufacture of near net-shape metal parts such as turbine blades and golf club heads.

Our products are sold primarily by our corporate account employees. We believe we are one of the leading global suppliers of colloidal silica.

### Additional Information

### International Operations

We directly operate in approximately 100 countries outside of the United States through wholly-owned subsidiaries or, in some cases, through a joint venture with a local partner. In certain countries, selected products are sold by our export operations to distributors, agents or licensees, although the volume of those sales is not significant in terms of our overall revenues. In general, our businesses conducted outside the United States are similar to those conducted in the United States.

Our business operations outside the United States are subject to the usual risks of foreign operations, including possible changes in trade and foreign investment laws, international business laws and regulations, tax laws, currency exchange rates and economic and political conditions. The profitability of our international operations is generally lower than the profitability of our businesses in the United States, due to (i) the additional cost of operating in numerous and diverse foreign jurisdictions with varying laws and regulations, (ii) higher costs of importing certain raw materials and finished goods in some regions, (iii) the smaller scale of international operations where certain operating locations are smaller in size, and (iv) the additional reliance on distributors and agents in certain countries which can negatively impact our margins. Proportionately larger investments in sales and technical support are also necessary in certain geographies in order to facilitate the growth of our international operations.

### Competition

In general, the markets in which the businesses in our Global Industrial reportable segment compete are led by a few large companies, with the rest of the market served by smaller entities focusing on more limited geographic regions or a smaller subset of products and services. Our businesses in this segment compete on the basis of their demonstrated value, technical expertise, innovation, digital technology, chemical formulations, global customer support, detection equipment, monitoring capabilities, and dosing and metering equipment. Through the combination of our digitally enabled end-to-end water management and hygiene solutions, data-driven insights and personalized service, our Global Industrial businesses deliver outcomes that help our customers optimize water and energy use, improve productivity, advance food safety, and achieve sustainability and net zero goals, while optimizing total cost of operations.

The businesses in our Global Institutional & Specialty reportable segment and Other have two significant classes of competitors. First, we compete with a small number of large companies selling directly or through distributors on a national or international scale. Second, we have numerous smaller regional or local competitors which focus on more limited geographies, product lines and/or end-use customer segments. We compete principally by providing superior value, premium customer support, training, service, and innovative and differentiated products to help our customers protect their brand reputation and improve their operational efficiency.

Within the Global Healthcare & Life Sciences reportable segment, the Healthcare business competes geographically with companies primarily focused on a smaller range of product categories, with few globally scaled competitors. Life Sciences business competes in the European market versus several mid-size and regional competitors and competes against two large and other mid-size or regional competitors in North America. Outside of North America and Europe competitors are much more fragmented and do not offer the same level of service or coverage as Ecolab. Our businesses in this segment compete by enabling our customers success through improved hygiene, digitally enabled programs in key operating room and patient room space as well as a tailored approach to delivering key inputs that directly impact our customers patients globally.

### Sales

Our products, systems and services are primarily marketed in domestic and international markets by our Company-trained direct field sales personnel who also advise and assist our customers in the proper and most efficient use of the products and systems in order to meet a full range of cleaning and sanitation, water treatment and process chemistry needs. Independent, third-party distributors and, to a lesser extent, sales agents, are utilized in several markets, as described in the segment descriptions found above.

### Customers and Classes of Products

We believe our business is not materially dependent upon a single customer. Additionally, although we have a diverse customer base and no customer or distributor constituted 10 percent or more of our consolidated revenues in 2021, 2020 or 2019, we do have customers and independent third-party distributors, the loss of which could have a material adverse effect on results of operations for the affected earnings periods; however, we consider it unlikely that such an event would have a material adverse impact on our financial position. No material part of our business is subject to renegotiation or termination at the election of a governmental unit.

We sold one class of products within the Global Institutional & Specialty reportable segment which comprised 10% or more of consolidated net sales in the last three years. Sales of warewashing products were approximately 10%, 11%, and 13% of consolidated net sales in 2021, 2020, and 2019, respectively.

### Human Capital

As of December 31, 2021, Ecolab employed approximately 47,000 employees, including approximately 25,000 sales and service and 1,200 research, development, and engineering employees. Approximately 42% of the employees are employed in North America, 21% in Europe, 8% in Asia Pacific, 18% in Latin America, 4% in India, Middle East and Africa, and 7% in Greater China.

We are committed to developing a culture that is diverse, equitable, inclusive, and fully leverages our employees’ talents as we work together to serve the needs of our customers. We believe in providing comprehensive training and career development opportunities and in compensating and rewarding our employees equitably. Our commitment to the safety of our employees, contractors and customers is evident in all we do, from the way we operate, to the products we develop and to the customers we serve. In addition, we are committed to promoting the health and well-being of our employees, our customers, and their customers by contributing to programs and initiatives that enhance the quality of life in the communities where they work and live. In support of these overall objectives, key areas of focus include:

*Diversity, Equity, and Inclusion:* We have a long-standing belief that a diverse, equitable, and inclusive workforce is a critical foundation for the shared success of our employees, our company, our customers, and our communities. To build that strong foundation, we have worked to embed diversity and inclusion throughout all people processes, including recruitment, promotional practices, training and development, and total rewards. To help guide our work and ensure a broad commitment to progress, Ecolab utilizes a Diversity Council made up of senior leaders throughout our company and chaired by our CEO. We review key metrics and practices, including diverse representation, hiring practices, and retention with the Council and with senior executives and business leads monthly. We set diversity goals at or above market availability and require diverse slates for all hiring activity. As a part of our 2030 impact goals, we have committed to the following:

- Committing to the UN Sustainable Development Goal 5: Gender Equality for Women and Girls
- Maintaining Ecolab’s pay equity in the U.S. and expanding globally
- Increasing management level gender diversity to 35% with the ultimate goal of gender parity
- Increasing management level ethnic/racial diversity to 25% as we seek to meet full representation of the U.S. workforce at all levels

We have a vibrant and growing community of Employee Resource Groups (ERGs) to help employees connect with colleagues, take part in career and leadership development experiences, and provide important insights in support of advancing our work in diversity, equity, and inclusion. These employee-led ERGs create community and focus across several dimensions of diversity, including gender, race/ethnicity, gender identity, sexual orientation, ability/disability, military service and more. All employees are welcome and encouraged to join, participate or become leaders within any of our 12 ERGs.

*Employee Training and Development:* At our core, Ecolab’s growth is rooted in decades of science, learning and innovation. We have ambitious solution-oriented teams and we continually look for ways to help our employees learn and grow. Beyond rigorous technical, functional, and business-specific training courses, our Global Corporate Flagship Development Programs are designed to deepen leadership capability and prepare successors for key leadership roles.

*Safety, Health and Wellness:* At Ecolab, the safety of our employees and contractors is our top priority and is embedded into our company values. Our safety goals are simple: zero accidents, zero injuries and zero violations. We communicate that this is a collective goal all employees commit to, own, and deliver on every day. Our leadership teams and a network of Safety, Health and Environment professionals around the world support employees with proven safety programs, processes, and platforms. Understanding underlying and potential risks is a critical component to improving safety outcomes. Our Global Safety Dashboard tracks our performance on a range of leading and lagging safety indicators and helps us measure the effectiveness of our safety programs.

Additionally, a Be Well Program is available to U.S. employees and their families to empower, educate and support their personal journey to overall well-being by making positive lifestyle choices while creating a culture of wellness throughout Ecolab. Over the last few years, we’ve expanded our offerings to include comprehensive child and elder caregiver resources to help employees balance the demands of work and personal responsibilities. To ensure the safety of our employees amidst an ongoing COVID-19 pandemic environment, we’ve continued to help our global employees garner access to vaccines and COVID-19 testing, have provided the option for employees who can do their work remotely to work from home, and have implemented additional safety measures for our employees working in the field and in our plant and warehouse locations.

*Future of Work*: Ecolab is committed to building a best-in-class, thriving work environment for all employees —from those who work in the field serving our customers, to those who work in our manufacturing facilities, to our employees who work in an office environment— our focus extends across all segments of our workforce. The Future of Work at Ecolab will embrace enhanced tools and technology and evolved practices to optimize performance, productivity, and collaboration. As we prepare to welcome more of our employees back to work in our Ecolab offices, we will offer a hybrid work model that balances evolving work practices and norms while preserving the practices we believe are core and fundamental to our success.

For additional detail regarding our Human Capital Management metrics and focus areas, please refer to our website for additional detail regarding our Human Capital Management metrics and focus areas, Diversity, Equity and Inclusion initiatives and other information and metrics, including our latest Corporate Responsibility GRI Report and EEO-1 report.

### Patents and Trademarks

We own and license a number of patents, trademarks and other intellectual property, including intellectual property from our recent acquisition of Purolite. While we have an active program to protect our intellectual property by filing for patents or trademarks and pursuing legal action, when appropriate, to prevent infringement, except for the items listed below, we do not believe our overall business is materially dependent on any individual patent or trademark.

- Patents related to our TRASAR and 3D TRASAR technology, which are material to our Global Industrial reportable segment. U.S. and foreign patents protect aspects of our key TRASAR and 3D TRASAR technology until at least 2024.
- Trademarks related to Ecolab, Nalco and 3D TRASAR, which collectively are material to all of our reportable segments. The Ecolab, Nalco and 3D TRASAR trademarks are registered or applied for in all of our key markets and we anticipate maintaining them indefinitely.

### Seasonality

We experience variability in our quarterly operating results due to seasonal sales volume and business mix fluctuations in our operating segments. Part II, Item 8, Note 20, entitled “Quarterly Financial Data” of this Form 10-K is incorporated herein by reference.

### Investments in Equipment

We have no unusual working capital requirements. We have invested in the past, and will continue to invest in the future, in process control and monitoring equipment consisting primarily of systems used by customers to dispense our products as well as to monitor water systems. The investment in such equipment is discussed under the heading "Investing Activities" in Management's Discussion and Analysis of Financial Condition and Results of Operations of this Form 10-K.

### Manufacturing and Distribution

We manufacture most of our products and related equipment in Company-operated manufacturing facilities. Some products are also produced for us by third-party contract manufacturers. Other products and equipment are purchased from third-party suppliers. Additional information on product/equipment sourcing is found in the segment discussions above and additional information on our manufacturing facilities is located under Part I, Item 2. “Properties,” of this Form 10-K.

Deliveries to customers are made from our manufacturing plants and a network of distribution centers and third-party logistics service providers. We use common carriers, our own delivery vehicles, and distributors for transport. Additional information on our plant and distribution facilities is located under Part I, Item 2. “Properties,” of this Form 10-K.

### Raw Materials

Raw materials purchased for use in manufacturing our products are inorganic chemicals, including alkalis, acids, biocides, phosphonates, phosphorous materials, silicates and salts; and organic chemicals, including acids, alcohols, amines, fatty acids, surfactants, solvents, monomers and polymers. Healthcare purchases plastic films and parts to manufacture medical devices that serve the surgical and infection prevention markets. Pesticides used by Pest Elimination are purchased as finished products under contract or purchase order from the producers or their distributors. We also purchase packaging materials for our manufactured products and components for our specialized cleaning equipment and systems. We purchase more than 10,000 raw materials, with the largest single raw material representing less than four percent of raw material purchases. Our raw materials, with the exception of a few specialized chemicals which we manufacture, are generally purchased on an annual contract basis and are ordinarily available in adequate quantities from a diverse group of suppliers globally. We have encountered supply chain disruptions from the impacts of the COVID-19 pandemic which has impacted the availability of certain raw materials; however, we believe this to be short-term in nature. When practical, global sourcing is used so that purchasing or production locations can be shifted to control product costs at globally competitive levels.

### Research and Development

Our research and development program consists principally of developing and validating the performance of new products, processes, techniques and equipment, improving the efficiency of those already existing, improving service program content, evaluating the environmental compatibility of products and technical support. Key disciplines include analytical and formulation chemistry, microbiology, data science and predictive analytics, process and packaging engineering, digital and remote monitoring engineering and product dispensing technology. Substantially all of our principal products have been developed by our research, development and engineering personnel.

We believe continued research and development activities are critical to maintaining our leadership position within the industry and will provide us with a competitive advantage as we seek additional business with new and existing customers.

### Joint Ventures

Over time, we have entered into partnerships or joint ventures in order to meet local ownership requirements, to achieve quicker operational scale, to expand our ability to provide our customers a more fully integrated offering or to provide other benefits to our business or customers. During 2021, the impact on our consolidated net income of our joint ventures, in the aggregate, was approximately three percent. We will continue to evaluate the potential for partnerships and joint ventures that can assist us in increasing our geographic, technological and product reach.

### Environmental and Regulatory Considerations

Our businesses are subject to various legislative enactments and regulations relating to the protection of the environment and public health. While we cooperate with governmental authorities and take commercially practicable measures to meet regulatory requirements and avoid or limit environmental effects, some risks are inherent in our businesses. Among the risks are costs associated with transporting and managing hazardous materials and waste disposal and plant site clean-up, fines and penalties if we are found to be in violation of law, as well as modifications, disruptions or discontinuation of certain operations or types of operations including product recalls and reformulations. Similarly, the need for certain of our products and services is dependent upon or might be limited by governmental laws and regulations. Changes in such laws and regulations, including among others, air, water, chemical and product regulations, could impact the sales of some of our products or services. In addition to an increase in costs of manufacturing and delivering products, a change in production regulations or product regulations could result in interruptions to our business and potentially cause economic or consequential losses should we be unable to meet the demands of our customers for products.

Additionally, although we are not currently aware of any such circumstances, there can be no assurance that future legislation or enforcement policies will not have a material adverse effect on our consolidated results of operations, financial position or cash flows. Environmental and regulatory matters most significant to us are discussed below.

***Ingredient Legislation***: Various laws and regulations have been enacted by state, local and foreign jurisdictions pertaining to the sale of products which contain phosphorous, volatile organic compounds, or other ingredients that may impact human health or the environment. Under California Proposition 65, for example, label disclosures are required for certain products containing chemicals listed by California. Chemical management initiatives that promote pollution prevention through research and development of safer chemicals and safer chemical processes are being advanced by several states.

Environmentally preferable purchasing programs for cleaning products have been enacted in a number of states to date, and in recent years have been considered by several other state legislatures. Cleaning product ingredient disclosure legislation has been introduced in the U.S. Congress in each of the past few years but has not passed, and several states are considering further regulations in this area. In 2017, California passed the Cleaning Product Right to Know Act of 2017, that required ingredient transparency on-line and on-label by 2020 and 2021, respectively. New York has proposed similar ingredient disclosure regulation. The U.S. Government is monitoring “green chemistry” initiatives through a variety of initiatives, including its “Design for the Environment” (“DfE”)/“Safer Choice” program. DfE/Safer Choice has three broad areas of work (recognition of safer products on a DfE/Safer Choice label, development of best practices for industrial processes and evaluation of safer chemicals), and we are involved in these to varying degrees. Our Global Institutional and Global Industrial cleaning products are subject to the regulations and may incur additional stay-in-market expenses associated with conducting the required alternatives analyses for chemicals of concern. To date, we generally have been able to comply with such legislative requirements by reformulation or labeling modifications. Such legislation has not had a material adverse effect on our consolidated results of operations, financial position or cash flows to date.

***TSCA***: The nation’s primary chemicals management law, the Toxic Substances Control Act (“TSCA”), was updated for the first time in 40 years with the passage of the Frank R. Lautenberg Chemical Safety for the 21st Century Act (“LCSA”) in 2016. The LCSA modernizes the original 1976 legislation, aiming to establish greater public confidence in the safety of chemical substances in commerce, improve the U.S. Environmental Protection Agency’s (“EPA”) capability and authority to regulate existing and new chemical substances, and prevent further state action or other notification programs like REACH (see below). For Ecolab, the TSCA changes mainly impact testing and submission costs for new chemical substances in the United States. In addition, the EPA likely will be more aggressively using the existing TSCA tools to manage chemicals of concern. We anticipate that compliance with new requirements under TSCA could be similar to the costs associated with REACH in the European Union, which is discussed below.

***REACH***: The European Union has enacted a regulatory framework for the Registration, Evaluation and Authorization of Chemicals (“REACH”), which aims to manage chemical safety risks. REACH established a European Chemicals Agency (“ECHA”) in Helsinki, Finland, which is responsible for evaluating data to determine hazards and risks and to manage this program for authorizing chemicals for sale and distribution in Europe. We met all REACH registration requirements. To help manage this program, we have been simplifying our product lines and working with chemical suppliers to comply with registration requirements. In addition, Korea, Taiwan, Turkey and other countries are implementing similar requirements. Potential costs to us are not yet fully quantifiable but are not expected to have a material adverse effect on our consolidated results of operations or cash flows in any one reporting period or on our financial position.

***GHS***: In 2003, the United Nations adopted a standard on hazard communication and labeling of chemical products known as the Globally Harmonized System of Classification and Labeling of Chemicals (“GHS”). GHS is designed to facilitate international trade and increase safe handling and use of hazardous chemicals through a worldwide system that classifies chemicals based on their intrinsic hazards and communicates information about those hazards through standardized product labels and safety data sheets (“SDSs”). Most countries in which we operate adopted GHS-related legislation by 2021. The primary cost of compliance revolves around reclassifying products and revising SDSs and product labels. We have met applicable deadlines and are working toward a phased-in approach to mitigate the costs of GHS implementation in remaining countries (e.g., Peru, Chile, India). Potential costs to us are not expected to have a material adverse effect on our consolidated results of operations or cash flows in any one reporting period or on our financial position.

***Pesticide and Biocide Legislation***: Various international, federal and state environmental laws and regulations govern the manufacture and/or use of pesticides. We manufacture and sell certain disinfecting, sanitizing and material preservation products that kill or reduce microorganisms (bacteria, viruses, fungi) on hard environmental surfaces, in process fluids and on certain food products. Such products constitute “pesticides” or “antimicrobial pesticides” under the current definitions of the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”), as amended by the Food Quality Protection Act of 1996, the principal federal statute governing the manufacture, labeling, handling and use of pesticides. We maintain several hundred product registrations with the U.S. Environmental Protection Agency (“EPA”). Registration entails the necessity to meet certain efficacy, toxicity and labeling requirements and to pay on-going registration fees. In addition, each state in which these products are sold requires registration and payment of a fee. In general, the states impose no substantive requirements different from those required by FIFRA. However, California and certain other states have adopted additional regulatory programs, and California imposes a tax on total pesticide sales in that state. While the cost of complying with rules as to pesticides has not had a material adverse effect on our consolidated results of operations, financial condition, or cash flows to date, the costs and delays in receiving necessary approvals for these products continue to increase. Total fees paid to the EPA and the states to obtain or maintain pesticide registrations are not expected to significantly affect our consolidated results of operations or cash flows in any one reporting period or our financial position.

In Europe, the Biocidal Products Regulation established a program to evaluate and authorize marketing of biocidal active substances and products. We are working with suppliers and industry groups to manage these requirements and have met all relevant deadlines of the program by the timely submission of dossiers for active substances and biocide products. Anticipated registration costs, which will be incurred through the multi-year phase-in period, will be significant; however, these costs are not expected to significantly affect our consolidated results of operations or cash flows in any one reporting period or our financial position. The same is true for emerging biocide regulations in Asia.

In addition, Pest Elimination applies restricted-use pesticides that it generally purchases from third parties. That business must comply with certain standards pertaining to the use of such pesticides and to the licensing of employees who apply such pesticides. Such regulations are enforced primarily by the states or local jurisdictions in conformity with federal regulations. We have not experienced material difficulties in complying with these requirements.

***FDA Antimicrobial Product Requirements***: Various laws and regulations have been enacted by federal, state, local and foreign jurisdictions regulating certain products manufactured and sold by us for controlling microbial growth on humans, animals and foods. In the United States, these requirements generally are administered by the U.S. Food and Drug Administration ("FDA"). However, the U.S. Department of Agriculture and EPA also may share in regulatory jurisdiction of antimicrobials applied to food. The FDA codifies regulations for these product categories in order to ensure product quality, safety and effectiveness. The FDA also has been expanding requirements applicable to such products, including proposing regulations for over-the-counter antiseptic drug products, which may impose additional requirements associated with antimicrobial hand care products and associated costs when finalized by the FDA. FDA regulations associated with the Food Safety Modernization Act may impose additional requirements related to safety product lines. To date, such requirements have not had a material adverse effect on our consolidated results of operations, financial position or cash flows.

***Medical Device and Drug Product Requirements***: As a manufacturer, distributor and marketer of medical devices and human drugs, we also are subject to regulation by the FDA and corresponding regulatory agencies of the state, local and foreign governments in which we sell our products. These regulations govern the development, testing, manufacturing, packaging, labeling, distribution and marketing of medical devices and medicinal products. We also are required to register with the FDA as a medical device and drug manufacturer, comply with post-market reporting (e.g., Adverse Event Reporting, MDR and Recall) requirements, and to comply with the FDA’s current Good Manufacturing Practices and Quality System Regulations which require that we have a quality system for the design and production of our products intended for commercial distribution in the United States and satisfy recordkeeping requirements with respect to our manufacturing, testing and control activities. Countries in the European Union require that certain products being sold within their jurisdictions obtain a “CE mark,” an international symbol of adherence to quality assurance standards, and be manufactured in compliance with certain requirements (e.g., Medical Device Directive 93/42/EE, Medical Device Regulation (EU) 2017/745, and ISO 13485). We have CE mark approval to sell various medical device and medicinal products in Europe. Our other international non-European operations also are subject to government regulation and country-specific rules and regulations. Regulators at the federal, state and local level have imposed, are currently considering and are expected to continue to impose regulations on medical devices and drug products. No prediction can be made of the potential effect of any such future regulations, and there can be no assurance that future legislation or regulations will not increase the costs of our products or prohibit the sale or use of certain products.

***Equipment:*** Ecolab’s products are dispensed by equipment that is subject to state and local regulatory requirements, as well as being subject to UL, NSF, and other approval requirements. For certain digitally connected product offerings, Federal Communication Commission (“FCC”) and corresponding international requirements are applicable. We have both dedicated manufacturing facilities and third-party production of our equipment. We are developing processes to monitor and manage changing regulatory regimes and assist with equipment systems compliance. To date, such requirements have not had a material adverse effect on our consolidated results of operations, financial position or cash flows.

***Other Environmental Legislation***: Our manufacturing plants are subject to federal, state, local or foreign jurisdiction laws and regulations relating to discharge of hazardous substances into the environment and to the transportation, handling and disposal of such substances. The primary federal statutes that apply to our activities in the United States are the Clean Air Act, the Clean Water Act and the Resource Conservation and Recovery Act. We are also subject to the Superfund Amendments and Reauthorization Act of 1986, which imposes certain reporting requirements as to emissions of hazardous substances into the air, land and water. The products we produce and distribute into Europe are also subject to directives governing electrical waste (WEEE Directive 2012/19/EU) and restrictive substances (RoHS Directive 2011/65/EU). Similar legal requirements apply to Ecolab’s facilities globally. We make capital investments and expenditures to comply with environmental laws and regulations, to promote employee safety and to carry out our announced environmental sustainability principles. To date, such expenditures have not had a significant adverse effect on our consolidated results of operations, financial position or cash flows. Our capital expenditures for environmental, health and safety projects worldwide were approximately $28 million in 2021 and $18 million in 2020. Approximately $50 million has been budgeted globally for projects in 2022. The increase in the projected spend reflects a return to historical annual expenditure levels prior to the COVID-19 pandemic.

***Climate Change***: Various laws and regulations pertaining to climate change have been implemented or are being considered for implementation at the international, national, regional and state levels, particularly as they relate to the reduction of greenhouse gas (GHG) emissions. We have not determined that any of these laws directly impact Ecolab at the present time; however, as a matter of corporate policy, we support a balanced approach to reducing GHG emissions while sustaining economic growth.

Furthermore, climate-related risks are assessed within our Enterprise Risk Management process and Annual Business Significance Risks Assessment, which is aligned with recommendations of the Financial Stability Board (FSB) Task Force on Climate-related Financial Disclosures (TCFD). We report TCFD disclosures in our annual CDP Climate report located at https://www.ecolab.com/sustainability/sustainability-reporting-resources. We are evaluating further application of the recommendations of the TCFD in alignment with the recommended timeline from the TCFD.

Ecolab recognizes that climate change poses potential risks and creates potential opportunities to our organization. Ecolab has taken steps to further identify and assess the nature and magnitude of these risks and opportunities. Ecolab has been focused on assessing climate risks for the past three years, leading up to our TCFD-aligned climate risk assessment conducted in 2021. We will continue our efforts to assess additional climate-related risks and opportunities including, exploring our supply chain resiliency. Subsequently, Ecolab will review the results of our analysis and develop adaptation and management plans for any relevant climate change risks and to further benefit from identified opportunities for customer impact.

To further bolster our climate commitment, in 2019 we announced new goals to reduce our GHG emissions by half by 2030 and achieve net zero by 2050, in alignment with the United Nations Global Compact’s Business Ambition for 1.5⁰C. In 2020, we further committed to move to 100% renewable energy by 2030 and set a science-based target (SBT) addressing our Scope 1, 2 and 3 GHG emissions. Our SBT commits us to reduce absolute Scope 1 and 2 emissions by 50% by 2030 from a 2018 base year, and to work with our suppliers representing 70% of our Scope 3 emissions to set science-based reduction targets by 2024.

In addition to managing our operational and supply chain sustainability performance, we partner with customers at more than three million customer locations around the world to reduce energy and GHG emissions through our high-efficiency solutions in cleaning and sanitation, water, paper, and energy services. Showcasing our global team’s dedication to helping our customers thrive and make a positive impact in the world, we have set a 2030 goal to help our customers reduce their GHG emissions by 6.0 million metric tons.

Ecolab recognizes the climate-water nexus. As part of our 2030 Impact Goals, we have committed to restore greater than 50% of our water withdrawal and achieve Alliance for Water Stewardship Standard certification in high-risk watersheds. In addition, we aim to reduce net water withdrawals by 40% per unit of production across our enterprise. We also magnify our impact through the water-saving solutions we deliver to our customers, and have set a goal to help our customers conserve more than 300 billion gallons of water annually by 2030.

***Environmental Remediation and Proceedings***: Along with numerous other potentially responsible parties (“PRP”), we are currently involved with waste disposal site clean-up activities imposed by the federal Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”) or state equivalents at 19 sites in the United States. Additionally, we have similar liability at three sites outside the United States. In general, under CERCLA, we and each other PRP that actually contributed hazardous substances to a Superfund site are jointly and severally liable for the costs associated with cleaning up the site. Customarily, the PRPs will work with the EPA to agree and implement a plan for site remediation.

Based on an analysis of our experience with such environmental proceedings, our estimated share of all hazardous materials deposited on the sites referred to in the preceding paragraph, and our estimate of the contribution to be made by other PRPs which we believe have the financial ability to pay their shares, we have accrued our best estimate of our probable future costs relating to such known sites. In establishing accruals, potential insurance reimbursements are not included. The accrual is not discounted. It is not feasible to predict when the amounts accrued will be paid due to the uncertainties inherent in the environmental remediation and associated regulatory processes.

We have also been named as a defendant in lawsuits where our products have not caused injuries, but the claimants wish to be monitored for potential future injuries. We cannot predict with certainty the outcome of any such tort claims or the involvement we or our products might have in such matters in the future, and there can be no assurance that the discovery of previously unknown conditions will not require significant expenditures. In each of these chemical exposure cases, our insurance carriers have accepted the claims on our behalf (with or without reservation) and our financial exposure should be limited to the amount of our deductible; however, we cannot predict the number of claims that we may have to defend in the future and we may not be able to continue to maintain such insurance.

We have also been named as a defendant in a number of lawsuits alleging personal injury due to exposure to hazardous substances, including multi-party lawsuits alleging personal injury in connection with our products and services. While we do not believe that any of these suits will be material to us based upon present information, there can be no assurance that these environmental matters could not have, either individually or in the aggregate, a material adverse effect on our consolidated results of operations, financial position or cash flows.

Our worldwide net expenditures for contamination remediation were approximately $0.5 million in 2021 and $0.6 million in 2020. Our worldwide accruals at December 31, 2021 for probable future remediation expenditures, excluding potential insurance reimbursements, totaled approximately $6.0 million. We review our exposure for contamination remediation costs periodically and our accruals are adjusted as considered appropriate. While the final resolution of these issues could result in costs below or above current accruals and, therefore, have an impact on our consolidated financial results in a future reporting period, we believe the ultimate resolution of these matters will not have a material effect on our consolidated results of operations, financial position or cash flows.

### Available Information.

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC at https://www.sec.gov.

General information about us, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as any amendments and exhibits to those reports, are available free of charge through our website at https://investor.ecolab.com as soon as reasonably practicable after we file them with, or furnish them to, the SEC.

In addition, the following governance materials are available on our web site at https://investor.ecolab.com/corporate-governance: (i) charters of the Audit, Compensation, Finance, Governance and Safety, Health and Environment Committees of our Board of Directors; (ii) our Board's Corporate Governance Principles; and (iii) our Code of Conduct.

We include our website addresses throughout this report for reference only. The information contained on our websites, including the corporate responsibility, EEO-1, and climate reports identified in this report, is not incorporated by reference into this report.

### Information about our Executive Officers.

The persons listed in the following table are our current executive officers. Officers are elected annually. There is no family relationship among any of the directors or executive officers and no executive officer has been involved during the past ten years in any legal proceedings described in applicable Securities and Exchange Commission regulations.

| Name ​ | ​ | Age ​ | ​ | Office ​ | ​ | Positions Held Since Jan. 1, 2017 ​ |
| --- | --- | --- | --- | --- | --- | --- |
| Douglas M. Baker, Jr. | ​ | 63 | ​ | Executive Chairman of the Board | ​ | Jan. 2021 – Present |
|  | ​ |  | ​ | Chairman of the Board and Chief Executive Officer | ​ | Jan. 2017 – Dec. 2020 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Christophe Beck | ​ | 54 | ​ | President and Chief Executive Officer | ​ | Jan. 2021 – Present |
| ​ | ​ | ​ | ​ | President and Chief Operating Officer | ​ | Apr. 2019 – Dec. 2020 |
| ​ | ​ | ​ | ​ | Executive Vice President and President – Industrial | ​ | May 2018 – Mar. 2019 |
| ​ | ​ | ​ | ​ | Executive Vice President and President – Global Nalco Water | ​ | May 2017 – May 2018 |
| ​ | ​ | ​ | ​ | Executive Vice President and President – Global Water & Process Services | ​ | Jan. 2017 – May 2017 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |

14

| Name |  | Age |  | Office |  | Positions Held Since Jan. 1, 2017 |
| --- | --- | --- | --- | --- | --- | --- |
| Larry L. Berger | ​ | 61 | ​ | Executive Vice President and Chief Technical Officer | ​ | Jan. 2017 – Present |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Jennifer J. Bradway | ​ | 45 | ​ | Senior Vice President and Corporate Controller | ​ | Jan. 2022 - Present |
| ​ | ​ | ​ | ​ | Senior Vice President and Controller, Global Institutional | ​ | Jan. 2020 – Dec. 2021 |
| ​ | ​ | ​ | ​ | Vice President Finance, Institutional North America | ​ | May 2018 – Dec. 2019 |
| ​ | ​ | ​ | ​ | Vice President and Controller, Institutional U.S. | ​ | Feb. 2017 – Apr. 2018 |
| ​ | ​ | ​ | ​ | Finance Director, Institutional U.S. Distribution | ​ | Jan. 2017 – Feb 2017 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Darrell R. Brown | ​ | 58 | ​ | Executive Vice President and President – Global Industrial | ​ | Apr. 2019 – Present |
| ​ | ​ | ​ | ​ | Executive Vice President and President – Energy Services | ​ | Jan. 2018 – Mar. 2019 |
| ​ | ​ | ​ | ​ | Executive Vice President, Global Downstream & WellChem | ​ | Apr. 2017 – Dec. 2017 |
| ​ | ​ | ​ | ​ | Executive Vice President and President – Europe | ​ | Jan. 2017 – Mar. 2017 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Angela M. Busch | ​ | 55 | ​ | Executive Vice President – Corporate Strategy & Business Development | ​ | Aug. 2018 – Present |
| ​ | ​ | ​ | ​ | Senior Vice President – Corporate Development | ​ | Jan. 2017 – Aug. 2018 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Alexander A. De Boo | ​ | 54 | ​ | Executive Vice President and President – Global Markets | ​ | Feb. 2021 - Present |
| ​ | ​ | ​ | ​ | Executive Vice President and President – Western Europe | ​ | Apr. 2020 – Jan. 2021 |
| ​ | ​ | ​ | ​ | Senior Vice President and General Manager – Industrial, Europe | ​ | Oct. 2018 – Apr. 2020 |
| ​ | ​ | ​ | ​ | Senior Vice President and General Manager – Food & Beverage, Europe | ​ | June 2017 – Oct. 2018 |
| ​ | ​ | ​ | ​ | Vice President and General Manager – Textile Care, Europe | ​ | Jan. 2017 – June 2017 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Machiel Duijser (1) | ​ | 50 | ​ | Executive Vice President and Chief Supply Chain Officer | ​ | Feb. 2020 – Present |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Scott D. Kirkland | ​ | 48 | ​ | Chief Financial Officer | ​ | Jan. 2022 – Present |
| ​ | ​ | ​ | ​ | Senior Vice President and Corporate Controller | ​ | June 2019 – Dec. 2021 |
| ​ | ​ | ​ | ​ | Senior Vice President – Finance, Global Energy Services | ​ | Jan. 2017 – May 2019 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Laurie M. Marsh | ​ | 58 | ​ | Executive Vice President – Human Resources | ​ | Jan. 2017 – Present |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Michael C. McCormick | ​ | 59 | ​ | Executive Vice President, General Counsel and Secretary | ​ | Oct. 2017 – Present |
| ​ | ​ | ​ | ​ | Executive Vice President, General Counsel and Assistant Secretary | ​ | Mar. 2017 – Sep. 2017 |
| ​ | ​ | ​ | ​ | Chief Compliance Officer, Deputy General Counsel and Assistant Secretary | ​ | Jan. 2017 – Feb. 2017 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Timothy P. Mulhere | ​ | 59 | ​ | Executive Vice President and President – Global Institutional & Specialty Services | ​ | Jan. 2020 – Present |
| ​ | ​ | ​ | ​ | Executive Vice President and President – Global Institutional | ​ | July 2018 – Jan. 2020 |
| ​ | ​ | ​ | ​ | Executive Vice President and President – Regions | ​ | Jan. 2017 – June 2018 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Gail Peterson | ​ | 43 | ​ | Senior Vice President – Global Marketing & Communications | ​ | Jan. 2021 – Present |
| ​ | ​ | ​ | ​ | Vice President – Marketing Global Healthcare | ​ | July 2017 – Dec. 2020 |
| ​ | ​ | ​ | ​ | Vice President – Corporate Strategy | ​ | Jan. 2017 – June 2017 |
| ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Elizabeth A. Simermeyer | ​ | 57 | ​ | Executive Vice President and President – Global Healthcare and Life Sciences | ​ | Dec. 2019 – Present |
| ​ | ​ | ​ | ​ | Executive Vice President – Global Marketing & Communications and Life Sciences | ​ | Jan. 2017– Dec. 2019 |

(1) Prior to joining Ecolab in February 2020, Mr. Duijser was employed by Reckitt Benckiser Group plc (RB), a global provider of health, hygiene and home products, as Chief Supply Officer since November 2018. Mr. Duijser joined RB from Amazon.com, Inc., a global service provider for e-commerce, cloud computing, digital streaming, and artificial intelligence, where he served as Vice President Worldwide Engineering from 2017 to 2018.

### Forward-Looking Statements

This Form 10-K, including Part I, Item 1, entitled “Business,” and the MD&A within Part II, Item 7, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include expectations concerning items such as:

- amount, funding and timing of cash expenditures relating to our restructuring and other initiatives, as well as savings from such initiatives
- future cash flows, access to capital, targeted credit rating metrics and impact of credit rating downgrade
- adequacy of cash reserves
- uses for cash, including dividends, share repurchases, debt repayments, capital investments and strategic business acquisitions
- global market risk
- long-term potential of our business
- impact of changes in exchange rates and interest rates
- customer retention rate
- bad debt experience, non-performance of counterparties and losses due to concentration of credit risk
- disputes, claims and litigation
- environmental contingencies
- impact and cost of complying with laws and regulations
- sustainability and human capital targets
- returns on pension plan assets
- contributions to pension and postretirement healthcare plans
- amortization expense
- impact of new accounting pronouncements
- income taxes, including tax attributes, valuation allowances, uncertain tax positions, permanent reinvestment assertions and goodwill deductibility
- recognition of share-based compensation expense
- payments under operating leases
- future benefit plan payments
- market position
- the impact of the Covid-19 pandemic, including global economic recovery, supply shortages, inflation and delivered product costs

Without limiting the foregoing, words or phrases such as “will likely result,” “are expected to,” “will be,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project” (including the negative or variations thereof), “intends,” “could,” or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. For a further discussion of these and other factors which could cause results to differ from those expressed in any forward-looking statement, see Item 1A of this Form 10-K, entitled “Risk Factors.” Except as may be required under applicable law, we undertake no duty to update our forward-looking statements.

## Risk factors

As filed, 41,192 characters.

The following are important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-K. See the section entitled “Forward-Looking Statements” set forth above.

We may also refer to this disclosure to identify factors that may cause results to differ materially from those expressed in other forward-looking statements including those made in oral presentations, including telephone conferences and/or webcasts open to the public.

### Economic & Operational Risks

***The COVID-19 pandemic and measures taken in response thereto have materially and adversely impacted, and we expect may continue to materially and adversely impact, our business and results of operations, and the full impact of the pandemic will depend on future developments, which are highly uncertain and cannot be predicted.***

Beginning in March 2020, the COVID-19 pandemic had a rapid and significant negative impact on the global economy, including a significant downturn in the foodservice, hospitality and travel industries. Measures taken to alleviate the pandemic (such as stay-at-home orders and other responsive measures) significantly impacted our restaurant and hospitality customers and negatively affected demand for our products and services in these segments, resulting in a material adverse effect on our business and results of operations. While many of these measures eased through the third quarter of 2021 driving increased consumer traffic and in-unit dining, the spread of COVID-19 variants resulted in restrictions on activities in the fourth quarter, particularly in geographies where vaccination rates lag, continuing to impact consumer activity. Concerns remain that our markets could see a prolonged resurgence of cases triggering additional government mandated lockdowns or similar restrictions. In addition, the COVID-19 pandemic continues to have a material effect on the macroeconomic environment, including significant supply chain disruptions resulting from labor shortages, disruptions to logistics networks and capacity constraints, and there is continued uncertainty around its duration and ultimate impact.

We expect the full impact of the COVID-19 pandemic, including the extent of its effect on our business, results of operations and financial condition, to be dictated by future developments which remain uncertain and cannot be predicted, such as the severity of the disease, the duration of the outbreak, the distribution, acceptance and efficacy of vaccines, the likelihood of a resurgence of the outbreak, including as a result of emerging variants, actions that may be taken by governmental authorities intended to minimize the spread of the pandemic or to stimulate the economy and other unintended consequences. In addition to the reduction in the demand for our products and services, the COVID-19 pandemic has had, and we expect will continue to have, certain negative impacts on our business, including, but not limited to, the following:

- We rely on a global workforce and take measures to protect the health and safety of our employees, customers and others with whom we do business while continuing to effectively manage our employees and maintain business operations. We have taken additional measures and incurred additional expenses to protect the health and safety of our employees to comply with applicable government requirements and safety guidance. Additionally, our business operations may be disrupted if a significant portion of our workforce is unable to work safely and effectively due to illness, quarantines, government actions or other restrictions or measures responsive to the pandemic, or if members of senior management or our Board of Directors are unable to perform their duties for an extended period of time. A significant outbreak in one of our manufacturing facilities could adversely impact our ability to make and ship products in a timely manner. Measures taken across our business operations to address health and safety may not be sufficient to prevent the spread of COVID-19 among our employee base, customers and others. Therefore, we could face operational disruptions and incur additional expenses, including devoting additional resources to assisting employees diagnosed with COVID-19 and further changing health and safety protocols and processes, that could adversely affect our business and results of operations.
- A significant number of our employees, as well as customers and others with whom we do business, continue to work remotely in response to the COVID-19 pandemic. Our business operations may be disrupted, and we may experience increased risk of adverse effects to our business, if our business operations are negatively impacted as a result of remote work arrangements, including due to cybersecurity risks or other disruption to our technology infrastructure. Further, if our key operating facilities experience closures or worker shortages as a result of COVID-19, whether temporary or sustained, our business operations could be significantly disrupted.
- We are subject to the mandatory vaccination and workplace safety protocols of Executive Order 14042 issued on September 9, 2021 and subsequent guidance issued thereunder by the Safer Federal Workforce Task Force. The Executive Order is currently stayed pending judicial review. This mandate, if enforceable, applies broadly to require covered federal contractor employees on covered contracts, those who perform duties in connection with a covered contract, and those working at the same workplace as covered employees, to be fully vaccinated for COVID-19, except for those that are legally entitled to an accommodation under applicable law. We may similarly be required to flow-down our obligations to certain of our subcontractors and suppliers. If it survives court challenge, the guidance remains subject to the interpretation of various government agencies and other entities, and questions remain regarding the specific application of the Executive Order and related guidance. As a result, if our understanding of its application to our workforce differs from our federal customers’ interpretation, or, despite our strong employee vaccination efforts, enough of our covered employees are unwilling to comply with the mandate, we may experience increased costs, business disruptions and attrition as a result of the mandate. Additionally, we may be subject to potential breach of contract claims, loss of business and assessment of fines if we or our affected subcontractors and suppliers are not able to fully comply in the time frame provided or if such subcontractors and suppliers choose to terminate their contract rather than comply.
- Cost management and various cost-containment actions implemented across our business in response to the COVID-19 pandemic could hinder execution of our business strategy, including the deferral of planned capital expenditures, and could adversely affect our business and results of operations.
- We believe that we appropriately reserve for expected credit losses; however, we cannot be certain that loss or delay in the collection of accounts receivable will not have a material adverse effect on our results of operations and financial condition.

***Our results could be materially and adversely affected by difficulties in securing the supply of certain raw materials or by fluctuations in the cost of raw materials.***

The prices of raw materials used in our business fluctuate, and in recent years we have experienced periods of significant increased raw material costs. Changes in raw material prices, unavailability of adequate and reasonably priced raw materials or substitutes for those raw materials, or the inability to obtain or renew supply agreements on favorable terms has materially and adversely affected our business and can in the future materially and adversely affect our consolidated results of operations, financial position or cash flows. In addition, volatility and disruption in economic activity and conditions could disrupt or delay the performance of our suppliers and thus impact our ability to obtain raw materials at favorable prices or on favorable terms, which may materially and adversely affect our business.

### Our results depend upon the continued vitality of the markets we serve.

Economic downturns, and in particular downturns in our larger markets including the foodservice, hospitality, travel, health care, food processing, refining, pulp and paper, mining and steel industries, can adversely impact our end-users. The last two years we have experienced the negative impact of the COVID-19 pandemic on the demand for our products and services provided to customers in the full-service restaurant, hospitality, lodging and entertainment industries. In prior years, the weaker global economic environment, particularly in Europe, has also negatively impacted certain of our end-markets. During these periods of weaker economic activity, our customers and potential customers may reduce or discontinue their volume of purchases of cleaning and sanitizing products and water treatment and process chemicals, which has had, and may continue to have, a material adverse effect on our business, financial condition, results of operation or cash flows.

### Our results are impacted by general worldwide economic factors.

Economic factors such as the worldwide economy, capital flows, interest rates and currency movements, including, in particular, our exposure to foreign currency risk, have affected our business in the past and may have a material adverse impact on our business in the future. For example, COVID-19 has impacted global supply chains for most products, as well as led to disruption and volatility in global capital markets, which increases the cost of capital and could potentially adversely impact access to capital. COVID-19 has caused similar volatility in foreign currency markets, increasing risk of unfavorable impacts on earnings due to significant FX rate movements. Recent political and economic upheaval in countries with Ecolab operations, such as Russia, Turkey, and Argentina, could also have a material adverse impact on our consolidated results of operations, financial position and cash flows by negatively impacting economic activity, including in our key end-markets, and by further weakening the local currency versus the U.S. dollar, resulting in reduced sales and earnings from our foreign operations, which are generated in the local currency, and then translated to U.S. dollars.

***We are subject to information technology system failures, network disruptions and breaches in data security.***

We rely to a large extent upon information technology systems and infrastructure to operate our business. The size and complexity of our information technology systems make them vulnerable to failure, malicious intrusion and random attack. Acquisitions have resulted in further de-centralization of systems and additional complexity in our systems infrastructure. Likewise, data security breaches by employees or others with permitted access to our systems pose a risk that sensitive data may be exposed to unauthorized persons or to the public. While we have invested in protection of data and information technology, we have experienced immaterial cybersecurity attacks and incidents, and there can be no assurance that our efforts will prevent failures, cybersecurity attacks or breaches in our systems that could cause reputational damage, business disruption or legal and regulatory costs; could result in third-party claims; could result in compromise or misappropriation of our intellectual property, trade secrets or sensitive information; or could otherwise adversely affect our business. Certain of our customer offerings include digital components, such as remote monitoring of certain customer operations. A breach of those remote monitoring systems could expose customer data giving rise to potential third-party claims and reputational damage. There may be other related challenges and risks as we complete implementation of our ERP system upgrade.

***We depend on key personnel to lead our business; the labor market is very dynamic in the wake of the Covid-19 pandemic.***

Our continued success will largely depend on our ability to attract, retain and develop a high caliber of talent and on the efforts and abilities of our executive officers and certain other key employees, particularly those with sales and sales management responsibilities to drive business growth, development and profitability. As we continue to grow our business, make acquisitions, expand our geographic scope and offer new products and services, we need the organizational talent necessary to ensure effective succession for executive officer and key employee roles in order to meet the growth, development and profitability goals of our business. Our operations could be materially and adversely affected if for any reason we were unable to attract, retain or develop such officers or key employees and successfully execute organizational change and management transitions at leadership levels. More generally, in the wake of the COVID-19 pandemic, expectations from qualified talent in many areas of the labor market have evolved. In light of this, if we are unable to attract and retain employees on terms and conditions that are consistent with our historical operating model, our business could be disrupted or our costs could increase, which may materially and adversely affect our business.

***Our significant non-U.S. operations expose us to global economic, political and legal risks that could impact our profitability.***

We have significant operations outside the United States, including joint ventures and other alliances. We conduct business in approximately 170 countries and, in 2021, approximately 48% of our net sales originated outside the United States. There are inherent risks in our international operations, including:

- exchange controls and currency restrictions;
- currency fluctuations and devaluations;
- tariffs and trade barriers;
- export duties and quotas;
- changes in the availability and pricing of raw materials, energy and utilities;
- changes in local economic conditions;
- changes in laws and regulations, including the imposition of economic or trade sanctions affecting international commercial transactions;
- impact from Brexit and the possibility of similar events in other EU member states;
- difficulties in managing international operations and the burden of complying with international and foreign laws;
- requirements to include local ownership or management in our business;
- economic and business objectives that differ from those of our joint venture partners;
- exposure to possible expropriation, nationalization or other government actions;
- restrictions on our ability to repatriate dividends from our subsidiaries;
- unsettled political conditions, military action, civil unrest, acts of terrorism, force majeure, war or other armed conflict; and
- countries whose governments have been hostile to U.S.-based businesses.

Changes in U.S. or foreign government policy on international trade, including the imposition or continuation of tariffs, could materially and adversely affect our business. In 2018, the U.S. imposed tariffs on certain imports from China and other countries, resulting in retaliatory tariffs by China and other countries. While the U.S. and China signed a Phase One trade agreement in January 2020, which included the suspension and rollback of tariffs, the U.S. Senate subsequently passed legislation in 2021 aimed at countering China’s technical ambitions and similar legislation was introduced in the House in 2022. Any new tariffs imposed by the U.S., China or other countries or any additional retaliatory measures by any of these countries, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations.

Also, because of uncertainties regarding the interpretation and application of laws and regulations and the enforceability of intellectual property and contract rights, we face risks in some countries that our intellectual property rights and contract rights would not be enforced by local governments. We are also periodically faced with the risk of economic uncertainty, which has impacted our business in some countries. Other risks in international business also include difficulties in staffing and managing local operations, including managing credit risk to local customers and distributors.

Further, our operations outside the United States require us to comply with a number of United States and non-U.S. laws and regulations, including anti-corruption laws such as the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, as well as U.S. and non-U.S. economic sanctions regulations. We have internal policies and procedures relating to such laws and regulations; however, there is risk that such policies and procedures will not always protect us from the misconduct or reckless acts of employees or representatives, particularly in the case of recently acquired operations that may not have significant training in applicable compliance policies and procedures. Violations of such laws and regulations could result in disruptive investigations, significant fines and sanctions, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows. In February 2022, following Russia’s invasion of Ukraine, the U.S. and other countries announced sanctions against Russia. The sanctions announced by the U.S. and other countries against Russia to date include restrictions on selling or importing goods, services or technology in or from affected regions, travel bans and asset freezes impacting connected individuals and political, military, business and financial organizations in Russia, severing Russia’s largest bank from the U.S. financial system, barring some Russian enterprises from raising money in the U.S. market and blocking the access of Russian banks to financial markets. The U.S. and other countries could impose wider sanctions and take other actions should the conflict further escalate. While it is difficult to anticipate the impact the sanctions announced to date may have on Ecolab, any further sanctions imposed or actions taken by the U.S. or other countries, and any retaliatory measures by Russia in response, such as restrictions on energy supplies from Russia to countries in the region, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations.

Our overall success as a global business depends, in part, upon our ability to succeed in differing economic, social, legal and political conditions. We may not continue to succeed in developing and implementing policies and strategies that are effective in each location where we do business, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

### Severe public health outbreaks may materially and adversely impact our business.

Our business could be adversely affected by the effect of a public health epidemic. Besides the COVID-19 pandemic, the United States and other countries have experienced, and may experience in the future, public health outbreaks such as Zika virus, Avian Flu, SARS and H1N1 influenza. A prolonged occurrence of a contagious disease such as these could result in a significant downturn in the foodservice, hospitality and travel industries and also may result in health or other government authorities imposing restrictions on travel further impacting our end markets. Any of these events could result in a significant drop in demand for some of our products and services and materially and adversely affect our business. Uncertainty with respect to the impact on our financial results of the COVID-19 pandemic is discussed further in Management Discussion & Analysis located at Part II, Item 7, of this form 10-K under the heading “Global Economic and Political Environment.”

### Strategic Risks

***If we are unsuccessful in executing on key business initiatives, including restructurings and our Enterprise Resource Planning (“ERP”) system upgrades, our business could be materially and adversely affected.***

We continue to execute key business initiatives, including restructurings and investments to develop business systems, as part of our ongoing efforts to improve our efficiency and returns. In particular, we are undertaking the Institutional Advancement Program and Accelerate 2020 plan to simplify and automate processes and tasks, reduce complexity and management layers, consolidate facilities and focus on key long term growth areas by leveraging technology and structural improvements as discussed under Note 3 entitled “Special (Gains) and Charges” of this Form 10-K. Additionally, we are continuing implementation of our ERP system upgrades, which are expected to continue in phases over the next several years. These upgrades, which include sales, supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades involve complex business process design and a failure of certain of these processes could result in business disruption. If the projects in which we are investing or the initiatives which we are pursuing are not successfully executed, our consolidated results of operations, financial position or cash flows could materially and adversely be affected.

***Our growth depends upon our ability to compete successfully with respect to value, innovation and customer support.***

We have numerous global, national, regional and local competitors. Our ability to compete depends in part on providing high quality and high value-added products, technology and service. We must also continue to identify, develop and commercialize innovative, profitable and high value-added products for niche applications and commercial digital applications. We have made significant investments in commercial digital product offerings, and our culture and expertise must continue to evolve to develop, support and profitably deploy commercial digital offerings, which are becoming an increasingly important part of our business. There can be no assurance that we will be able to accomplish our technology development goals or that technological developments by our competitors will not place certain of our products, technology or services at a competitive disadvantage in the future. In addition, certain of the new products that we have under development will be offered in markets in which we do not currently compete, and there can be no assurance that we will be able to compete successfully in those new markets. If we fail to introduce new technologies or commercialize our digital offerings on a timely and profitable basis, we may lose market share and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

***Consolidation of our customers and vendors could materially and adversely affect our results.***

Customers and vendors in the foodservice, hospitality, travel, healthcare, energy, life sciences, food processing and pulp and paper industries, as well as other industries we serve, have consolidated in recent years and that trend may continue. This consolidation could have a material adverse impact on our ability to retain customers and on our pricing, margins and consolidated results of operations.

### We enter into multi-year contracts with customers that could impact our results.

Our multi-year contracts with some of our customers include terms affecting our pricing flexibility. There can be no assurance that these restraints will not have a material adverse impact on our margins and consolidated results of operations.

### We may not realize the anticipated benefits of the Purolite acquisition.

We recently acquired Purolite, which operates in the highly regulated life sciences, pharma and biopharma industries and has extensive international operations which complicate integration execution. If we have difficulty integrating Purolite operations or lose key employees or customers, our business could be materially and adversely affected.

***If we are unsuccessful in integrating acquisitions, our business could be materially and adversely affected.***

As part of our long-term strategy, we seek to acquire complementary businesses. There can be no assurance that we will find attractive acquisition candidates or succeed at effectively managing the integration of acquired businesses into existing businesses. If the underlying business performance of such acquired businesses deteriorates, the expected synergies from such transactions do not materialize or we fail to successfully integrate new businesses into our existing businesses, our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

### Legal, Regulatory & Compliance Risks

***Our business depends on our ability to comply with laws and governmental regulations and meet our contractual commitments and failure to do so could materially and adversely impact our business; and we may be materially and adversely affected by changes in laws and regulations.***

Our business is subject to numerous laws and regulations relating to the environment, including evolving climate change standards, and to the manufacture, storage, distribution, sale and use of our products as well as to the conduct of our business generally, including employment and labor laws and anti-corruption laws. Compliance with these laws and regulations exposes us to potential financial liability and increases our operating costs. A violation of these laws and regulations could expose us to financial liability that may have a material adverse effect on our results of operations and cash flows. Regulation of our products and operations continues to increase with more stringent standards, causing increased costs of operations and potential for liability if a violation occurs. The potential cost to us relating to environmental and product registration laws and regulations is uncertain due to factors such as the unknown magnitude and type of possible contamination and clean-up costs, the complexity and evolving nature of laws and regulations, and the timing and expense of compliance. Changes to current laws (including tax laws), regulations and policies could impose new restrictions, costs or prohibitions on our current practices which would have a material adverse effect on our consolidated results of operations, financial position or cash flows. Changes to labor and employment laws and regulations, as well as related rulings by courts and administrative bodies, could materially and adversely affect our operations and expose us to potential financial liability.

Defense of litigation, particularly certain types of actions such as antitrust, patent infringement, personal injury, product liability, breach of contract, wage hour and class action lawsuits, can be costly and time consuming even if ultimately successful, and if not successful could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

### A chemical spill or release could materially and adversely impact our business.

As a manufacturer and supplier of chemical products, there is a potential for chemicals to be accidentally spilled, released or discharged, either in liquid or gaseous form, during production, transportation, storage or use. Such a release could result in environmental contamination as well as a human or animal health hazard. Accordingly, such a release could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

***Potential indemnification liabilities pursuant to the separation and split-off of our Upstream Energy business could materially and adversely affect our business and financial statements.***

With respect to the separation and subsequent split-off of our Upstream Energy business, we entered into a separation and distribution agreement with ChampionX Holding Inc. and ChampionX Corporation (f/k/a Apergy Corporation and taken together with ChampionX Holding Inc., “ChampionX”) as well as certain other agreements to govern the separation and related transactions and our relationship with ChampionX going forward. These agreements provide for specific indemnity and certain other obligations of each party and could lead to disputes between ChampionX and us. If we are required to indemnify ChampionX under the circumstances set forth in these agreements, we may be subject to substantial related liabilities. In addition, with respect to the liabilities for which ChampionX has agreed to indemnify us under these agreements, there can be no assurance that the indemnity rights we have against ChampionX will be sufficient to protect us against the full amount of such liabilities, or that ChampionX will be able to fully satisfy its indemnification obligations. Each of these risks could negatively affect our business and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

### Extraordinary events may significantly impact our business.

The occurrence of (a) litigation or claims, (b) the loss or insolvency of a major customer or distributor, (c) repeated or prolonged federal government shutdowns or similar events, (d) war (including acts of terrorism or hostilities which impact our markets), (e) natural or manmade disasters, (f) water shortages or (g) severe weather conditions affecting our operations or the energy, foodservice, hospitality and travel industries may have a material adverse effect on our business.

While we have a diverse customer base and no customer or distributor constitutes 10 percent or more of our consolidated revenues, we do have customers and independent, third-party distributors, the loss of which could have a material adverse effect on our consolidated results of operations or cash flows for the affected earnings periods.

Government shutdowns can have a material adverse effect on our consolidated results of operations or cash flows by disrupting or delaying new product launches, renewals of registrations for existing products and receipt of import or export licenses for raw materials or products.

War (including acts of terrorism or hostilities), natural or manmade disasters, water shortages or severe weather conditions affecting the energy, foodservice, hospitality, travel, health care, food processing, pulp and paper, mining, steel and other industries can cause a downturn in the business of our customers, which in turn can have a material adverse effect on our consolidated results of operations, financial position or cash flows. In particular, the U.S. Gulf Coast is a region with significant refining, petrochemicals and chemicals operations which provide us raw materials, as well as being an important customer base for our Downstream and Water operating segments. Hurricanes or other severe weather events impacting the Gulf Coast, such as the winter freeze in Texas and the Gulf Coast in February 2021, can materially and adversely affect our ability to obtain raw materials at reasonable cost, or at all, and could adversely affect our business with our customers in the region.

### Financial Risks

***If the separation and split-off of our Upstream Energy business or certain internal transactions undertaken in anticipation of the divestiture are determined to be taxable in whole or in part, we and our stockholders may incur significant tax liabilities.***

In connection with the separation and split-off of our Upstream Energy business that was consummated on June 3, 2020, we obtained opinions of outside tax counsel that the related merger and exchange offer will qualify as tax-free transactions to us and our stockholders, except to the extent that cash was paid to Ecolab stockholders in lieu of fractional shares. We have not sought or obtained a ruling from the Internal Revenue Service (IRS) on the tax consequences of these transactions. An opinion of counsel is not binding on the IRS or the courts, which may disagree with the opinion. Even if the merger and exchange offer otherwise qualified as tax-free transactions, they may become taxable to us if certain events occur that affect either Ecolab or ChampionX Corporation. While ChampionX Corporation has agreed not to take certain actions that could cause the transactions not to qualify as tax-free transactions and is generally obligated to indemnify us against any tax consequences if it breaches this agreement, the potential tax liabilities could have a material adverse effect on us if we were not entitled to indemnification or if the indemnification obligations were not fulfilled. If the merger or exchange offer were determined to be taxable, we could be subject to a substantial tax liability, and each U.S. holder of our common stock who participated in the exchange offer could be treated as exchanging the Ecolab shares surrendered for ChampionX Corporation shares in a taxable transaction.

***Changes in tax laws and unanticipated tax liabilities could materially and adversely affect the taxes we pay and our profitability.***

We are subject to income and other taxes in the United States and foreign jurisdictions, and our operations, plans and results are affected by tax and other initiatives around the world. In particular, we are affected by the impact of changes to tax laws or related authoritative interpretations in the United States. While the ultimate adoption of new tax legislation is uncertain, it is possible that any such legislation may include increases to the tax rates at which income of U.S. companies would be taxed. We are also subject to changes in tax law outside the United States and actions taken with respect to tax-related matters by associations such as the Organization for Economic Co-operation and Development (“OECD”), which represents a coalition of member countries, and the European Commission which influence tax policies in countries where we operate. For example, approximately 140 countries have agreed to the OECD’s two-pillar base erosion and profit shifting project (“BEPS”). This framework, which is expected to be implemented in some countries beginning in 2023, is focused on a number of issues, including shifting taxing rights on income from residence countries to source countries and establishing a minimum 15% global tax rate. Some of the BEPS and related proposals, if enacted into law in the United States and in the foreign countries where we do business, could increase the burden and costs of our tax compliance, the amount of taxes we incur in those jurisdictions and our global effective tax rate. In addition, we are impacted by settlements of pending or any future adjustments proposed by the IRS or other taxing authorities in connection with our tax audits, all of which will depend on their timing, nature and scope. Increases in income tax rates, changes in income tax laws or unfavorable resolution of tax matters could have a material adverse impact on our financial results.

***Future events may impact our deferred tax position, including the utilization of foreign tax credits and undistributed earnings of international affiliates that are considered to be reinvested indefinitely.***

We evaluate the recoverability of deferred tax assets and the need for deferred tax liabilities based on available evidence. This process involves significant management judgment about assumptions that are subject to change from period to period based on changes in tax laws or variances between future projected operating performance and actual results. We are required to establish a valuation allowance for deferred tax assets if we determine, based on available evidence at the time the determination is made, that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making this determination, we evaluate all positive and negative evidence as of the end of each reporting period. Future adjustments (either increases or decreases), to the deferred tax asset valuation allowance are determined based upon changes in the expected realization of the net deferred tax assets. The realization of the deferred tax assets ultimately depends on the existence of sufficient taxable income in either the carry-back or carry-forward periods under the tax law. Due to significant estimates used to establish the valuation allowance and the potential for changes in facts and circumstances, it is reasonably possible that we will be required to record adjustments to the valuation allowance in future reporting periods. Changes to the valuation allowance or the amount of deferred tax liabilities could have a material adverse effect on our consolidated results of operations or financial position. Further, should we change our assertion regarding the permanent reinvestment of the undistributed earnings of international affiliates, a deferred tax liability may need to be established.

***Our indebtedness may limit our operations and our use of our cash flow, and any failure to comply with the covenants that apply to our indebtedness could materially and adversely affect our liquidity and financial statements.***

As of December 31, 2021, we had approximately $8.8 billion in outstanding indebtedness, with approximately $1.7 billion in the form of floating rate debt. Our debt level and related debt service obligations may have negative consequences, including:

- requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt, which reduces the funds we have available for other purposes such as acquisitions and capital investment;
- reducing our flexibility in planning for or reacting to changes in our business and market conditions;
- exposing us to interest rate risk since a portion of our debt obligations are at variable rates. For example, a one percentage point increase in the average interest rate on our floating rate debt at December 31, 2021 would increase future interest expense by approximately $17 million per year; and
- increasing our cost of funds and materially and adversely affecting our liquidity and access to the capital markets should we fail to maintain the credit ratings assigned to us by independent rating agencies.

If we add new debt, the risks described above could increase.

***We incur significant expenses related to the amortization of intangible assets and may be required to report losses resulting from the impairment of goodwill or other assets recorded in connection with the Nalco transaction and other acquisitions.***

We expect to continue to complete selected acquisitions and joint venture transactions in the future. In connection with acquisition and joint venture transactions, applicable accounting rules generally require the tangible and intangible assets of the acquired business to be recorded on the balance sheet of the acquiring company at their fair values. Intangible assets other than goodwill are required to be amortized over their estimated useful lives and this expense may be significant. Any excess in the purchase price paid by the acquiring company over the fair value of tangible and intangible assets of the acquired business is recorded as goodwill. If it is later determined that the anticipated future cash flows from the acquired business may be less than the carrying values of the assets and goodwill of the acquired business, the assets or goodwill may be deemed to be impaired. In this case, the acquiring company may be required under applicable accounting rules to write down the value of the assets or goodwill on its balance sheet to reflect the extent of the impairment. This write-down of assets or goodwill is generally recognized as a non-cash expense in the statement of operations of the acquiring company for the accounting period during which the write down occurs. As of December 31, 2021, we had goodwill of $8.1 billion which is maintained in various reporting units, including goodwill from the Nalco and Purolite transactions. If we determine that any of the assets or goodwill recorded in connection with the Nalco transaction or any other prior or future acquisitions or joint venture transactions have become impaired, we will be required to record a loss resulting from the impairment. Impairment losses could be significant and could have a material adverse effect on our consolidated results of operations and financial position.

## Properties

As filed, 10,772 characters.

Our manufacturing philosophy is to manufacture products wherever an economic, process or quality assurance advantage exists or where proprietary manufacturing techniques dictate in-house production. Currently, most products that we sell are manufactured at our facilities. We position our manufacturing locations and warehouses in a manner to permit ready access to our customers.

Our manufacturing facilities produce chemical products as well as medical devices and equipment for all of our operating segments, although Pest Elimination purchases the majority of their products and equipment from outside suppliers. Our chemical production process consists of blending purchased raw materials into finished products in powder, liquid, and solid form. Additionally, intermediates from reaction chemistries are used in some of the blends and are also packaged directly into finished goods. Our devices and equipment manufacturing operations consist of producing chemical product dispensers and injectors and other mechanical equipment, medical devices, dishwasher racks, related sundries, dish machine refurbishment and water monitoring and maintenance equipment system from purchased components and subassemblies.

The following table profiles our more significant physical properties with approximately 70,000 square feet or more with ongoing production activities, as well as certain other facilities important in terms of specialization and sources of supply. In general, manufacturing facilities located in the United States serve our U.S. markets and facilities located outside of the United States serve our international markets. However, most of the United States facilities do manufacture products for export.

### PLANT PROFILES

| Location |  | Approximate Size (Sq. Ft.) |  | Segment |  | Majority Owned or Leased |
| --- | --- | ---: | --- | --- | --- | --- |
| Joliet, IL USA |  | 610,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Asheville, NC USA | ​ | 478,000 | ​ | Global Industrial, Global Healthcare & Life Sciences | ​ | Leased |
| Tai Cang, CHINA |  | 468,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Hongzhou, CHINA | ​ | 430,125 | ​ | Global Healthcare & Life Sciences | ​ | Owned |
| Sainghin, FRANCE |  | 360,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Mandras, GREECE | ​ | 355,435 | ​ | Global Industrial, Global Healthcare & Life Sciences | ​ | Owned |
| Victoria, ROMANIA | ​ | 343,605 | ​ | Global Healthcare & Life Sciences | ​ | Owned |

23

| Location |  | Approximate Size (Sq. Ft.) |  | Segment |  | Majority Owned or Leased |
| --- | --- | ---: | --- | --- | --- | --- |
| South Beloit, IL USA |  | 313,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences, Other |  | Owned |
| Jianghai, CHINA |  | 296,000 |  | Global Industrial |  | Owned |
| Chalons, FRANCE |  | 280,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Clearing, IL USA |  | 270,000 |  | Global Industrial, Global Healthcare & Life Sciences, Other (Colloidal) |  | Owned |
| Nanjing, CHINA |  | 240,000 |  | Global Industrial |  | Owned |
| Garland, TX USA |  | 239,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Philadelphia, PA USA | ​ | 232,000 | ​ | Global Healthcare & Life Sciences | ​ | Owned |
| Martinsburg, WV USA |  | 228,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Elwood City, PA USA |  | 222,000 |  | Global Industrial |  | Owned |
| Weavergate, UNITED KINGDOM |  | 222,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Celra, SPAIN |  | 218,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Greensboro, NC USA |  | 193,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Owned |
| Fresno, TX USA |  | 192,000 |  | Global Industrial |  | Owned |
| Santiago, CHILE | ​ | 188,000 | ​ | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences | ​ | Owned |
| Las Americas, DOMINICAN REPUBLIC |  | 182,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Owned |
| Jacksonville, FL USA |  | 181,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased |
| Garyville, LA USA |  | 178,000 |  | Global Industrial |  | Owned |
| Gul Lane, SINGAPORE | ​ | 169,000 | ​ | Global Industrial |  | Owned |
| Nieuwegein, NETHERLANDS |  | 168,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| La Romana, DOMINICAN REPUBLIC |  | 160,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased |
| Middleton, UNITED KINGDOM | ​ | 157,575 | ​ | Global Industrial, Global Healthcare & Life Sciences | ​ | Owned |
| Tessenderlo, BELGIUM |  | 153,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Cheltenham, AUSTRALIA |  | 145,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Suzano, BRAZIL |  | 142,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| McDonough, GA USA |  | 141,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Darra, AUSTRALIA |  | 138,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Burlington, ON CANADA |  | 136,000 |  | Global Industrial |  | Owned |
| Eagan, MN USA |  | 133,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences, Other |  | Owned |
| Huntington, IN USA |  | 127,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Rozzano, ITALY |  | 126,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| City of Industry, CA USA |  | 125,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Mississauga, ON CANADA |  | 120,000 |  | Global Institutional & Specialty, Global Industrial |  | Leased |
| Elk Grove Village, IL USA |  | 115,000 |  | Global Institutional & Specialty |  | Leased |
| Biebesheim, GERMANY |  | 109,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Fort Worth, TX USA |  | 101,000 |  | Global Institutional & Specialty |  | Leased |
| Johannesburg, SOUTH AFRICA |  | 100,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Andover, UNITED KINGDOM | ​ | 99,762 | ​ | Global Industrial, Global Healthcare & Life Sciences | ​ | Owned |
| Pilar, ARGENTINA | ​ | 96,000 | ​ | Global Institutional & Specialty, Global Industrial | ​ | Owned |
| Hamilton, NEW ZEALAND |  | 96,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Konnagar, INDIA | ​ | 88,000 | ​ | Global Industrial |  | Owned |

24

| Location |  | Approximate Size (Sq. Ft.) |  | Segment |  | Majority Owned or Leased |
| --- | --- | ---: | --- | --- | --- | --- |
| Kwinana, AUSTRALIA |  | 87,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Yangsan, KOREA |  | 85,000 |  | Global Industrial |  | Owned |
| Cuautitlan, MEXICO |  | 76,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Barueri, BRAZIL |  | 75,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Leased |
| Citereup, INDONESIA | ​ | 74,000 | ​ | Global Industrial | ​ | Owned |
| Mullingar, IRELAND |  | 74,000 |  | Global Institutional & Specialty, Global Industrial |  | Leased |
| Mosta, MALTA |  | 73,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased |
| Aubagne, FRANCE |  | 65,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased |
| Siegsdorf, GERMANY |  | 56,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |
| Verona, ITALY |  | 55,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Owned |
| Guangzhou, CHINA |  | 55,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Navanakorn, THAILAND |  | 53,000 |  | Global Institutional & Specialty, Global Industrial |  | Leased |
| Lerma, MEXICO |  | 49,000 |  | Global Industrial |  | Owned |
| Maribor, SLOVENIA |  | 46,400 |  | Global Institutional & Specialty, Global Industrial |  | Owned |
| Leeds, UNITED KINGDOM |  | 25,000 |  | Global Institutional & Specialty |  | Owned |
| Baglan, UNITED KINGDOM |  | 24,400 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased |
| Noda, JAPAN |  | 22,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned |

Generally, our manufacturing facilities are adequate to meet our existing in-house production needs. We continue to invest in our plant sites to maintain viable operations and to add capacity as necessary to meet business imperatives.

Most of our manufacturing plants also serve as distribution centers. In addition, we operate distribution centers around the world, most of which are leased, and utilize third party logistics service providers to facilitate the distribution of our products and services.

Our corporate headquarters is comprised of a 17-story building that we own in St. Paul, Minnesota. We also own a 90-acre campus in Eagan, Minnesota that houses a significant research and development center, a data center and training facilities as well as several of our administrative functions. We also have a significant business presence in Naperville, Illinois, where our Water and Paper operating segments maintain their principal administrative offices and research center, as well as in Greensboro, North Carolina, where our Specialty operating segment maintains its principal administrative offices and a research center. Our Downstream operating segment leases administrative and research facilities in Sugar Land, Texas and maintains additional Company-owned research facilities in Fresno, Texas.

Significant regional administrative and/or research facilities are located in Campinas, Brazil; Leiden, Netherlands; and Pune, India, which we own, and in Dubai, UAE; Monheim, Germany; Singapore; Shanghai, China; and Zurich, Switzerland, which we lease. We also have a network of small leased sales offices in the United States and, to a lesser extent, in other parts of the world.

## Legal proceedings

As filed, 406 characters.

Discussion of legal proceedings is incorporated by reference from Part II, Item 8, Note 16, “Commitments and Contingencies,” of this Form 10-K and should be considered an integral part of Part I, Item 3, “Legal Proceedings.”

Discussion of other environmental-related legal proceedings is incorporated by reference from Part I, Item 1 above, under the heading “Environmental and Regulatory Considerations.”

## Management's discussion and analysis

As filed, 114,784 characters.

The following management discussion and analysis (“MD&A”) provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

The discussion should be read in conjunction with the consolidated financial statements and related notes included in this Form 10-K. Our consolidated financial statements are prepared in accordance with U.S. GAAP. This discussion contains various Non-GAAP Financial Measures and also contains various forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements and information set forth in the sections entitled “Non-GAAP Financial Measures” at the end of this MD&A, and “Forward-Looking Statements” and “Risk Factors” within Items 1 and 1A of this Form 10-K. We also refer readers to the tables within the section entitled “Results of Operations” of this MD&A for reconciliation information of Non-GAAP measures to U.S. GAAP.

### Comparability of Results

### Purolite acquisition

On December 1, 2021, we acquired Purolite for total consideration of $3.7 billion in cash. Purolite is a leading and fast-growing global provider of high-end ion exchange resins for the separation and purification of solutions for pharmaceutical and industrial applications. Headquartered in King of Prussia, Pennsylvania, Purolite operates in more than 30 countries. Purolite is reported within our Life Sciences operating segment. Acquisition and integration charges are recorded within special (gains) and charges.

In addition, the remaining impacts of the Purolite acquisition including operating results, acquisition-related amortization and interest expense related to the transaction have also been excluded from adjusted results.

### ChampionX Transaction

On June 3, 2020, we completed the previously announced separation of our Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX Business, followed immediately by the merger of ChampionX (the “Merger”) with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

The ChampionX business met the criteria to be reported as discontinued operations because the separation of ChampionX was a strategic shift in business that had a major effect on our operations and financial results. Therefore, we report the historical results of ChampionX, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations for all periods presented herein. Unless otherwise noted, the accompanying MD&A has been revised to reflect the ChampionX business as discontinued operations and prior year balances have been revised accordingly to reflect continuing operations only.

### Comparability of Reportable Segments

Effective in the first quarter of 2020, and in anticipation of the separation of the Upstream Energy business, we created the Upstream and Downstream operating segments from the Global Energy operating segment, which was also a reportable segment. Subsequent to the separation of ChampionX, we no longer report the Upstream Energy segment, which previously held the ChampionX business.

The Downstream operating segment has been aggregated into the Global Industrial reportable segment. Also, in the first quarter of 2020, we announced leadership changes which allow for shared oversight and focus on the Healthcare and Life Sciences operating segments and established the Global Healthcare & Life Sciences reportable segment. This segment is comprised of the Healthcare operating segment which was previously aggregated in the Global Institutional reportable segment and the Life Sciences operating segment which was previously aggregated in the Global Industrial reportable segment. Additionally, the Textile Care operating segment, which is now being reported in Other, had previously been aggregated in the Global Industrial reportable segment. We also renamed the Global Institutional reportable segment to the Global Institutional & Specialty reportable segment. We made other immaterial changes, including the movement of certain customers and cost allocations between reportable segments.

### Impact of Acquisitions and Divestitures

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition, the results of our divested businesses from the twelve months prior to divestiture and the Venezuelan results of operations from all comparable periods. As part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

### Fixed Currency Foreign Exchange Rates

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the “Segment Performance” section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

### EXECUTIVE SUMMARY

In 2021, we delivered strong sales performance in an environment where COVID-19 infections impacted business activity and further disrupted global supply chains which together, impacted the global recovery. Delivered product cost inflation and other supply constraints increased significantly but we undertook extraordinary measures to assure our customers were supplied with our critical products and services. Double-digit sales growth in the Institutional & Specialty and Other segments along with strong Industrial segment growth more than offset the Healthcare & Life Sciences segment’s decline versus a very strong gain last year. Accelerating pricing and higher volume more than offset significantly higher delivered product costs and supply constraints, including the impact of Texas Freeze and Hurricane Ida, and the comparison to lower variable compensation last year.

### Sales

Reported sales increased 8% to $12.7 billion in 2021 from $11.8 billion in 2020. When measured in fixed rates of foreign currency exchange, fixed currency sales increased 6% compared to the prior year. Acquisition adjusted fixed currency sales increased 5% compared to the prior year.

### Gross Margin

Our reported gross margin was 40.2% of sales for 2021, compared to our 2020 reported gross margin of 41.4%. Excluding the impact of special (gains) and charges and impacts from the Purolite transaction included in cost of sales from both 2021 and 2020, our adjusted gross margin was 40.9% in 2021 and 41.8% in 2020.

### Operating Income

Reported operating income increased 15% to $1.6 billion in 2021, compared to $1.4 billion in 2020. Adjusted operating income, excluding the impact of special (gains) and charges and the impacts of the Purolite transaction, increased 11% in 2021. When measured in fixed rates of foreign currency exchange, adjusted fixed currency operating income increased 8% in 2021.

### Earnings from Continuing Operations Attributable to Ecolab Per Common Share (“EPS”)

Reported continuing operations diluted EPS increased 17% to $3.91 in 2021 compared to $3.33 in 2020. Special (gains) and charges had an impact on both years. Special (gains) and charges in 2021 include COVID-19 related charges, restructuring charges, debt refinancing charges, acquisition and integration charges, and litigation and other charges. Special (gains) and charges in 2020 include debt refinancing charges, restructuring charges, disposal and impairment charges, Healthcare product recall charges, acquisition and integration charges, COVID-19 related charges, and litigation and other charges. Special (gains) and charges in 2019 were driven primarily by the impact of restructuring charges, discrete tax items, acquisition and integration charges and litigation and other charges. The impact of the Purolite transaction was $0.02 per share dilutive to reported earnings per share from continuing operations (excluding special charges) as sales since its December 1, 2021 acquisition were more than offset by acquisition-related amortization and interest expense. Adjusted continuing operations diluted EPS, which exclude the impact of special (gains) and charges, the impacts of the Purolite transaction and discrete tax items increased 17% to $4.69 in 2021 compared to $4.02 in 2020.

### Balance Sheet

We remain committed to maintaining “A” range ratings metrics over the long-term, supported by our current credit ratings of A-/A3/A- by Standard & Poor’s, Moody’s Investor Services and Fitch, respectively. Our strong balance sheet has allowed us continued access to capital at attractive rates.

### Net Debt to EBITDA

Our net debt to earnings before interest, taxes, depreciation and amortization (“EBITDA”) was 3.4 and 2.4 for 2021 and 2020, respectively. We view these ratios as important indicators of the operational and financial health of our organization. See the “Net Debt to EBITDA” table on page 44 for reconciliation information.

### Cash Flow

Cash flow from continuing operations operating activities was $2.1 billion in 2021 compared to $1.7 billion in 2020. We continued to generate strong cash flow from operations, allowing us to fund our ongoing operations, investments in our business, acquisitions, debt repayments, pension obligations and return cash to our shareholders through share repurchases and dividend payments.

### Dividends

We increased our quarterly cash dividend 6% in December 2021, bringing annual dividends declared to $1.95 per share. The increase represents our 30th consecutive annual dividend rate increase and the 85th consecutive year we have paid cash dividends. Our outstanding dividend history reflects our long term growth and development, strong cash flows, solid financial position and confidence in our business prospects for the years ahead.

### CRITICAL ACCOUNTING ESTIMATES

Our consolidated financial statements are prepared in accordance with U.S. GAAP. We have adopted various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 2 of the Notes to the Consolidated Financial Statements (“Notes”).

Preparation of our consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions to be made about matters that are highly uncertain at the time the accounting estimate is made, and (2) different estimates that we reasonably could have used for the accounting estimate in the current period, or changes in the accounting estimate that are reasonably likely to occur from period to period, have a material impact on the presentation of our financial condition or results of operations.

In March 2020, COVID-19 was declared a pandemic by the World Health Organization. As the impact of the pandemic continues to evolve, estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require judgment. These estimates and assumptions may change in future periods and will be recognized in the consolidated financial information as new events occur and additional information becomes known. To the extent actual results differ materially from those estimates and assumptions, our future financial statements could be affected.

Besides estimates that meet the “critical” estimate criteria, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues or expenses as well as disclosures of contingent assets and liabilities. Estimates are based on experience and other information available prior to the issuance of the financial statements. Materially different results can occur as circumstances change and additional information becomes known, even from estimates not deemed critical. Our critical accounting estimates include the following:

### Revenue Recognition

Revenue is measured as the amount of consideration expected to be received in exchange for transferring goods or providing service. Revenue from product and sold equipment is recognized when obligations under the terms of a contract with the customer are satisfied, which generally occurs with the transfer of the product or delivery of the equipment. Revenue from service and leased equipment is recognized when the services are provided, or the customer receives the benefit from the leased equipment, which is over time. Service revenue is recognized over time utilizing an input method and aligns with when the services are provided. Typically, revenue is recognized over time using costs incurred to date because the effort provided by the field selling and service organization represents services provided, which corresponds with the transfer of control. Revenue for leased equipment is accounted for under Topic 842 Leases and recognized on a straight-line basis over the length of the lease contract.

Our revenue policies do not provide for general rights of return. We record estimated reductions to revenue for customer programs and incentive offerings including pricing arrangements, promotions and other volume-based incentives based primarily on historical experience and anticipated performance over the contract period. Depending on market conditions, we may increase customer incentive offerings, which could reduce gross profit margins over the term of the incentive. We also record estimated reserves for product returns and credits based on specific circumstances and credit conditions. We record an allowance for uncollectible accounts based on our estimates of expected future credit losses.

The revenue standard can be applied to a portfolio of contracts with similar characteristics if it is reasonable that the effects of applying the standard at the portfolio would not be significantly different than applying the standard at the individual contract level. We apply the portfolio approach primarily within each operating segment by geographical region. Application of the portfolio approach was focused on those characteristics that have the most significant accounting consequences in terms of their effect on the timing of revenue recognition or the amount of revenue recognized. We determined the key criteria to assess with respect to the portfolio approach, including the related deliverables, the characteristics of the customers and the timing and transfer of goods and services, which most closely aligned within the operating segments. In addition, the accountability for the business operations, as well as the operational decisions on how to go to market and the product offerings, are performed at the operating segment level. For additional information on revenue recognition, refer to Note 18.

### Litigation and Environmental Liabilities

Our business and operations are subject to extensive environmental laws and regulations governing, among other things, air emissions, wastewater discharges, the use and handling of hazardous substances, waste disposal and the investigation and remediation of soil and groundwater contamination. Some risk of environmental liability is inherent in our operations.

We record liabilities related to pending litigation, environmental claims and other contingencies when a loss is probable and can be reasonably estimated. Estimates used to record such liabilities are based on our best estimate of probable future costs. We record the amounts that represent the points in the range of estimates that we believe are most probable or the minimum amount when no amount within the range is a better estimate than any other amount. Potential insurance reimbursements generally are not anticipated in our accruals for environmental liabilities or other insured losses. Expected insurance proceeds are recorded as receivables when recovery is deemed certain. While the final resolution of litigation and environmental contingencies could result in amounts different than current accruals, and therefore have an impact on our consolidated financial results in a future reporting period, we believe the ultimate outcome will not have a significant impact on our consolidated financial position. For additional information on our commitments and contingencies, refer to Note 16.

### Actuarially Determined Liabilities

### Pension and Postretirement Healthcare Benefit Plans

The measurement of our pension and postretirement benefit obligations are dependent on a variety of assumptions determined by management and used by our actuaries. These assumptions affect the amount and timing of future contributions and expenses.

The significant assumptions used in developing the required estimates are the discount rate, expected return on assets, projected salary and health care cost increases and mortality table.

- The discount rate assumptions for our U.S. plans are assessed using a yield curve constructed from a subset of bonds yielding greater than the median return from a population of non-callable, corporate bond issues that have an average rating of AA when averaging available Moody’s Investor Services, Standard & Poor’s and Fitch ratings. The discount rate is calculated by matching the plans’ projected cash flows to the bond yield curve. For 2021 and 2020, we measured service and interest costs by applying the

specific spot rates along that yield curve to the plans’ liability cash flows. We believe this approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve. In determining our U.S. pension obligations for 2021, our weighted-average discount rate increased to 2.86% from 2.48% at year-end 2020. In determining our U.S. postretirement health care obligation for 2021, our weighted-average discount rate increased to 2.75% from 2.37% at year-end 2020.

- The expected rate of return on plan assets reflects asset allocations, investment strategies and views of investment advisors, and represents our expected long-term return on plan assets. Our weighted-average expected return on U.S. plan assets used in determining the U.S. pension and U.S. postretirement health care expenses was 7.00% for 2021, 7.25% for 2020 and 7.25% for 2019.
- Projected salary and health care cost increases are based on our long-term actual experience, the near-term outlook and assumed inflation. Our weighted-average projected salary increase used in determining the U.S. pension expenses was 4.03% for 2021, 2020 and 2019.
- For postretirement benefit measurement purposes as of December 31, 2021, the annual rates of increase in the per capita cost of covered health care were assumed to be 6.75% for pre-65 costs and 7.25% for post-65 costs. The rates are assumed to decrease each year until they reach 4.5% in 2029 and remain at those levels thereafter.
- In determining our U.S. pension and U.S. postretirement health care obligation for 2021, we utilized the most recent mortality table, MP-2021 projection scale (applied to the Pri-2012 mortality table).

The effects of actual results differing from our assumptions, as well as changes in assumptions, are reflected in the unrecognized actuarial loss and amortized over future periods and, therefore, will generally affect our recognized expense in future periods. Significant differences in actual experience or significant changes in assumptions may materially affect future pension and other postretirement obligations and expense. The unrecognized net actuarial loss on our U.S. qualified and non-qualified pension plans decreased to $397 million as of December 31, 2021 from $691 million as of December 31, 2020 (both before tax), primarily due to current year net actuarial gains.

The effect of a decrease in the discount rate or decrease in the expected return on assets assumption as of December 31, 2021, on the December 31, 2021 defined benefit obligation and 2022 expense is shown below, assuming no changes in benefit levels and no amortization of gains or losses for our significant U.S. plans. Expense amounts reflect the accounting for actuarial gains as a component of other comprehensive income and recognition of the impacts into income over the remaining service period:

| ​ ​ ​ ​ ​ ​ ​ ​ (millions) ​ | ​ Effect on U.S. Pension Plans ​ Assumption Change | ​ ​ ​ ​ | ​ Increase in Recorded Obligation | ​ | ​ | ​ ​ ​ ​ | ​ Higher 2022 Expense | ​ | ​ |
| --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Discount rate | -0.25 pts | ​ | ​ | $65.6 | ​ | ​ | ​ | $3.3 | ​ |
| Expected return on assets | -0.25 pts | ​ | ​ | N/A | ​ | ​ | ​ | 5.3 | ​ |

| ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (millions) ​ | ​ Effect on U.S. Postretirement Health Care Benefits Plans ​ Assumption Change | ​ ​ ​ ​ | ​ Increase in Recorded Obligation | ​ | ​ | ​ ​ ​ ​ | ​ Higher 2022 Expense | ​ | ​ |
| --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Discount rate | -0.25 pts |  | ​ | $4.4 | ​ |  | ​ | $0.1 | ​ |
| Expected return on assets | -0.25 pts | ​ |  | N/A | ​ | ​ | ​ | - | ​ |

Our international pension obligations and underlying plan assets represent approximately one third of our global pension plans, with the majority of the amounts held in the U.K. and Eurozone countries. We use assumptions similar to our U.S. plan assumptions to measure our international pension obligations, however, the assumptions used vary by country based on specific local country requirements and information.

Refer to Note 17 for further discussion concerning our accounting policies, estimates, funded status, contributions and overall financial positions of our pension and postretirement plan obligations.

### Self-Insurance

Globally we have insurance policies with varying deductible levels for property and casualty losses. We are insured for losses in excess of these deductibles, subject to policy terms and conditions and have recorded both a liability and an offsetting receivable for amounts in excess of these deductibles. We are self-insured for health care claims for eligible participating employees, subject to certain deductibles and limitations. We determine our liabilities for claims on an actuarial basis.

### Income Taxes

Judgment is required to determine the annual effective income tax rate, deferred tax assets and liabilities, valuation allowances recorded against net deferred tax assets and uncertain tax positions.

### Effective Income Tax Rate

Our effective income tax rate is based on annual income, statutory tax rates and tax planning available in the various jurisdictions in which we operate. Our annual effective income tax rate includes the impact of reserve provisions. We recognize the amount of tax benefit that is greater than 50% likely of being realized upon settlement with a taxing authority. We adjust these reserves in light of changing facts and circumstances.

Tax regulations require items to be included in our tax returns at different times than the items are reflected in our financial statements. As a result, the effective income tax rate reflected in our financial statements differs from that reported in our tax returns. Some of these differences are permanent, such as expenses that are not deductible on our tax return, and some are temporary differences, such as depreciation expense.

### Deferred Tax Assets and Liabilities and Valuation Allowances

Deferred tax assets and liabilities are determined based on temporary differences between the financial reporting and tax bases of assets and liabilities, applying enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Based on the evaluation of available evidence, both positive and negative, we recognize tax assets, such as net operating loss carryforwards and tax credit carryforwards, to the extent that realizing these benefits is considered to be more likely than not. Relevant factors in determining the realizability of deferred tax assets include historical results, sources of future taxable income, the expected timing of the reversal of temporary differences, tax planning strategies and the expiration dates of the various tax attributes.

### Uncertain Tax Positions

A number of years may elapse before a particular tax matter, for which we have established a liability for uncertain tax position, is audited and finally resolved. The number of tax years with open tax audits varies depending on the tax jurisdiction. The Internal Revenue Service (“IRS”) has completed examinations of our U.S. federal income tax returns through 2016 and the years 2017 and 2018 are currently under audit. In addition to the U.S. federal examinations, we have ongoing audit activity in several U.S. state and foreign jurisdictions.

The tax positions we take are based on our interpretations of tax laws and regulations in the applicable federal, state and international jurisdictions. We believe our tax returns properly reflect the tax consequences of our operations, and our liabilities for uncertain tax positions are appropriate and sufficient for the positions taken. Because of the uncertainty of the final outcome of these examinations, we have reserved for potential reductions of tax benefits (including related interest and penalties) for amounts that do not meet the more-likely-than-not thresholds for recognition and measurement as required by authoritative guidance. The liability for uncertain tax positions is reviewed throughout the year, taking into account new legislation, regulations, case law and audit results. Settlement of any particular issue could result in offsets to other balance sheet accounts, cash payments or receipts and/or adjustments to tax expense. Liabilities for uncertain tax positions are presented in the Consolidated Balance Sheets within other non-current liabilities. Our gross liability for uncertain tax positions was $25 million and $21 million as of December 31, 2021 and 2020, respectively. For additional information on income taxes refer to Note 13.

### Long-Lived Assets, Intangible Assets and Goodwill

### Long-Lived and Amortizable Intangible Assets

Long-lived and amortizable intangible assets acquired are recorded on the acquisition date at their respective fair values based on the fair value requirements defined in U.S. GAAP. This requires us to make significant estimates and assumptions relating to the present value of its future cash flows, such as growth rates, royalty rates or discount rates.

We review our long-lived and amortizable intangible assets, the net value of which was $6.8 billion and $5.3 billion as of December 31, 2021 and 2020, respectively, for impairment when significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset or asset group, a significant adverse change in the manner in which asset or asset groups are being used or history of operating or cash flow losses associated with the use of the asset or asset group. Impairment losses could occur when the carrying amount of an asset or asset group exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset or asset group and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated as the excess of the asset’s or assets group’s carrying amount over its estimated fair value.

We use the straight-line method to recognize amortization expense related to our amortizable intangible assets, including our customer relationships. We consider various factors when determining the appropriate method of amortization for our customer relationships, including projected sales data, customer attrition rates and length of key customer relationships.

Globally, we have a broad customer base. Our retention rate of significant customers has aligned with our acquisition assumptions, including the customer bases acquired from our Nalco, Anios, CID Lines and Purolite transactions, which make up the majority of our unamortized customer relationships. Our historical retention rate, coupled with our consistent track record of keeping long-term relationships with our customers, supports our expectation of consistent sales generation for the foreseeable future from the acquired customer bases. If our customer retention rates or other post-acquisition operational activities change materially, we would evaluate the financial impact and significances of the events given rise to the change which could result in impairment of our customer relationship intangible assets, or absent an impairment, an acceleration of amortization.

In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would impact the amount of depreciation and amortization expense recorded in earnings. We have experienced no significant changes in the carrying amount or estimated remaining useful lives of our long-lived or amortizable intangible assets.

### Goodwill and Indefinite Life Intangible Assets

We had total goodwill of $8.1 billion and $6.0 billion as of December 31, 2021 and 2020, respectively. We test our goodwill for impairment at the reporting unit level on an annual basis during the second quarter. Our reporting units are aligned with our eleven operating segments.

For our annual 2021 goodwill impairment assessment, we completed a quantitative impairment assessment for each of our eleven reporting units using discounted cash flow analyses that incorporated assumptions, including future operating performance, long-term growth, and discount rates. Our goodwill impairment assessments for 2021 indicated the estimated fair values of each of our reporting units exceeded the carrying amounts of the respective reporting units by a significant margin. We assess the need to test our reporting units for impairment during interim periods between our scheduled annual assessments when significant events or changes in business circumstances indicate that it is more likely than not that the carrying amount of a reporting unit may be higher than its fair value. Additionally, no events noted during the second half of 2021 indicated a need to update any of our analyses or conclusions reached in the second quarter of 2021 for any of our eleven reporting units. There has been no impairment of goodwill in any of the periods presented.

The Nalco trade name is our only indefinite life intangible asset. During the second quarter of 2021, we completed our annual impairment assessment of the Nalco trade name using the relief from royalty discounted cash flow method, which incorporates assumptions, including future sales projections, royalty rates and discount rates. Our Nalco tradename impairment assessment for 2021 indicated the estimated fair value of the Nalco trade name exceeded its $1.2 billion carrying amount by a significant margin. There has been no impairment of the Nalco trade name intangible since it was acquired.

### RESULTS OF OPERATIONS

### Net Sales

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ Percent Change ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ ​ 2020 |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | --- |
| Product and equipment sales | **​** | **​** | **$10,153.3** | **​** |  | ​ | $9,466.6 | ​ |  | ​ | $10,129.0 | ​ |  | **​** **​** | **​** | ​ ​ |
| Service and lease sales | **​** | **​** | **2,579.8** | **​** | **​** | ​ | 2,323.6 | ​ | ​ | ​ | 2,433.0 | ​ | **​** | **​** **​** | **​** | ​ ​ |
| Reported GAAP net sales | **​** | **​** | **12,733.1** | **​** | **​** | ​ | 11,790.2 | ​ | ​ | ​ | 12,562.0 | ​ | **​** | **8%** | **​** | (6)% |
| Impact of Purolite on net sales | **​** | **​** | **12.0** | **​** | **​** | ​ | - | ​ | ​ | ​ | - | ​ | **​** | **​** **​** | **​** | ​ ​ |
| Non-GAAP adjusted net sales | **​** | **​** | **12,721.1** | **​** | **​** | ​ | 11,790.2 | ​ | ​ | ​ | 12,562.0 | ​ | **​** | **8%** | **​** | (6)% |
| Effect of foreign currency translation | **​** |  | **111.7** | **​** |  |  | 332.1 | ​ | ​ |  | 241.2 | ​ | ​ | **​** **​** | **​** | ​ ​ |
| Non-GAAP adjusted fixed currency sales | **​** | **​** | **$12,832.8** | **​** | **​** | ​ | $12,122.3 | ​ | ​ | ​ | $12,803.2 | ​ | ​ | **6%** | **​** | (5)% |
| ​ | **​** | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | **​** **​** | **​** | ​ ​ |

The percentage components of the year-over-year sales change are shown below:

| ​ (percent) | ​ ​ ​ | ​ 2021 | ​ ​ | ​ ​ ​ | ​ ​ 2020 |
| --- | --- | --- | ---: | --- | ---: |
| Volume | ​ | ​ | **3%** | ​ | (9)% |
| Price changes | ​ | ​ | **2** **​** | ​ | 2 ​ |
| Acquisition adjusted fixed currency sales change | ​ | ​ | **5** **​** | ​ | (7) ​ |
| Acquisitions & divestitures | ​ | ​ | **1** **​** | ​ | 2 ​ |
| Fixed currency sales change | ​ | ​ | **6** **​** | ​ | (5) ​ |
| Foreign currency translation | ​ | ​ | **2** **​** | ​ | (1) ​ |
| Reported GAAP net sales change | ​ | ​ | **8%** | ​ | (6)% |

Amounts do not necessarily sum due to rounding.

### Cost of Sales (“COS”) and Gross Profit Margin (“Gross Margin”)

| ​ ​ ​ (millions/percent) | ​ 2021 ​ ​ | ​ ​ COS | ​ ​ ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ | ​ 2020 ​ ​ | ​ ​ COS | ​ ​ ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ | ​ 2019 ​ ​ | ​ ​ COS | ​ ​ ​ | ​ ​ | ​ ​ Gross Margin |
| --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- |
| Product and equipment cost of sales | ​ | **$6,100.9** | ​ | ​ | ​ ​ | ​ | ​ | $5,481.3 | ​ | ​ | ​ ​ | ​ | ​ | $5,617.5 | ​ | ​ | ​ ​ |
| Service and lease cost of sales | ​ | **1,514.9** | ​ | ​ | ​ ​ | ​ | ​ | 1,424.5 | ​ | ​ | ​ ​ | ​ | ​ | 1,428.3 | ​ | ​ | ​ ​ |
| Reported GAAP COS and gross margin | **​** | **7,615.8** | **​** | **​** | **40.2%** | **​** | ​ | 6,905.8 | ​ | ​ | 41.4% | ​ | ​ | 7,045.8 | ​ | ​ | 43.9% |
| Special (gains) and charges | **​** | **93.9** | **​** | **​** | ​ **​** | ​ | ​ | 48.2 | ​ | ​ | ​ ​ | ​ |  | 38.5 | ​ |  | ​ ​ |
| Impact of Purolite on COS | **​** | **7.6** | **​** | **​** | ​ **​** | ​ | ​ | - | ​ | ​ | ​ ​ | ​ | ​ | - | ​ | ​ | ​ ​ |
| Non-GAAP adjusted COS and gross margin | **​** | **$7,514.3** | **​** | **​** | **40.9%** | ​ | ​ | $6,857.6 | ​ | ​ | 41.8% | ​ | ​ | $7,007.3 | ​ | ​ | 44.2% |

Our COS values and corresponding gross margin are shown above. Our gross margin is defined as sales less cost of sales divided by sales.

Our reported gross margin was 40.2%, 41.4%, and 43.9% for 2021, 2020, and 2019, respectively. Our 2021, 2020 and 2019 reported gross margins were negatively impacted by special (gains) and charges of $93.9 million, $48.2 million, and $38.5 million, respectively. Special (gains) and charges items impacting COS are shown within the “Special (Gains) and Charges” table below.

Excluding the impact of special (gains) and charges and the impacts of the Purolite transaction, our 2021 adjusted gross margin was 40.9% compared against a 2020 adjusted gross margin of 41.8%. The decrease primarily reflected increased pricing and higher volumes which were more than offset by significantly higher delivered product costs and supply constraints, including the impact of the Texas Freeze and Hurricane Ida.

Excluding the impact of special (gains) and charges, our adjusted gross margin was 41.8% and 44.2% for 2020 and 2019, respectively. The decrease primarily reflected the impact of lower volume, reduced operating leverage and unfavorable business mix, which more than offset pricing.

### Selling, General and Administrative Expenses (“SG&A”)

| ​ ​ (percent) | ​ ​ 2021 | ​ ​ | ​ ​ 2020 | ​ ​ | ​ ​ 2019 |
| --- | ---: | --- | ---: | --- | ---: |
| SG&A Ratio | **26.8%** | **​** | 28.1% | ​ | 28.3% |

The decreased SG&A ratio (SG&A expenses as a percentage of reported net sales) comparing 2021 against 2020 was driven primarily by higher net sales, cost savings initiatives and reduction in bad debt, partially offset by higher variable compensation compared to last year. The decreased SG&A ratio comparing 2020 against 2019 was driven primarily by lower incentive compensation, discretionary spend reductions and cost savings initiatives which offset the effects of lower sales.

### Special (Gains) and Charges

Special (gains) and charges reported on the Consolidated Statements of Income included the following items:

| ​ ​ (millions) Cost of sales | ​ ​ ​ ​ | ​ ​ 2021 ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ 2020 ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ 2019 ​ | ​ ​ ​ | ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Restructuring activities | ​ |  | **$24.7** | **​** | ​ |  | $7.4 | ​ | ​ | ​ | $20.4 | ​ |
| Acquisition and integration activities | ​ | **​** | **4.2** | **​** | ​ | ​ | 3.9 | ​ | ​ | ​ | 7.6 | ​ |
| COVID-19 activities, net | ​ | **​** | **64.7** | **​** | ​ | ​ | 12.5 | ​ | ​ | ​ | - | ​ |
| Other | ​ | **​** | **0.3** | **​** | ​ | ​ | 24.4 | ​ | ​ | ​ | 10.5 | ​ |
| Cost of sales subtotal | ​ |  | **93.9** | **​** | ​ |  | 48.2 | ​ |  |  | 38.5 | ​ |
| ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Special (gains) and charges | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Restructuring activities | ​ |  | **11.9** | **​** | ​ |  | 71.4 | ​ | ​ | ​ | 93.2 | ​ |
| Acquisition and integration activities | ​ | **​** | **29.9** | **​** | ​ | ​ | 8.5 | ​ | ​ | ​ | 5.6 | ​ |
| Disposal and impairment activities | ​ | **​** | **-** | **​** | ​ | ​ | 41.4 | ​ | ​ | ​ | - | ​ |
| COVID-19 activities, net | ​ | **​** | **42.4** | **​** | ​ | ​ | 23.6 | ​ | ​ | ​ | - | ​ |
| Other | ​ |  | **18.4** | **​** | ​ |  | 34.7 | ​ | ​ | ​ | 21.4 | ​ |
| Special (gains) and charges subtotal | ​ |  | **102.6** | **​** | ​ |  | 179.6 | ​ |  |  | 120.2 | ​ |
| ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Operating income subtotal | ​ | **​** | **196.5** | **​** | ​ | ​ | 227.8 | ​ | ​ | ​ | 158.7 | ​ |
| ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Other (income) expense | ​ | **​** | **37.2** | **​** | ​ | ​ | 0.4 | ​ | ​ | ​ | 9.5 | ​ |
| Interest expense, net | ​ | **​** | **33.1** | **​** | ​ | ​ | 83.8 | ​ | ​ | ​ | 0.2 | ​ |
| ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Total special (gains) and charges | ​ | **​** | **$266.8** | **​** | ​ | ​ | $312.0 | ​ | ​ | ​ | $168.4 | ​ |

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting.

### Restructuring Activities

Restructuring activities are primarily related to the Institutional Advancement Program and Accelerate 2020, both of which are described below. These activities have been included as a component of cost of sales, special (gains) and charges, and other (income) expense on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets.

Further details related to our restructuring charges are included in Note 3.

#### Institutional Advancement Program

We approved a restructuring plan in 2020 focused on the Institutional business (“the Institutional Plan”) which is intended to enhance our Institutional sales and service structure and allow the sales team to capture share and penetration while maximizing service effectiveness by leveraging our ongoing investments in digital technology. In February 2021, we expanded the Institutional Plan, and expect that these restructuring charges will be completed by 2023, with total anticipated costs of $65 million ($50 million after tax) or $0.17 per diluted share. The costs are expected to be primarily cash expenditures for severance and facility closures. We also anticipate non-cash charges related to equipment disposals. Actual costs may vary from these estimates depending on actions taken.

In 2021, we recorded total restructuring charges of $12.6 million ($10.2 million after tax) or $0.04 per diluted share, primarily related to severance, disposals of equipment and office closures. We have recorded $47.8 million ($36.6 million after tax), or $0.13 per diluted share of cumulative restructuring charges under the Institutional Plan. The liability related to the Institutional Plan was $5.1 million as of December 31, 2021. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters which continue to be funded from operating activities.

The Institutional Plan has delivered $41 million of cumulative cost savings with estimated annual cost savings of $50 million in continuing operations by 2024.

#### Accelerate 2020

During 2018, we formally commenced a restructuring plan Accelerate 2020 (“the Plan”), to leverage technology and system investments and organizational changes. The goal of the Plan is to further simplify and automate processes and tasks, reduce complexity and management layers, consolidated facilities and focus on key long-term growth areas by further leveraging technology and structural improvements. During 2020, we expanded the Plan for additional costs and savings to further leverage the technology and structural improvements. Following the establishment of the separate Institutional Plan, we now expect that the restructuring activities will be completed by the end of 2022, with total anticipated costs of $255 million ($195 million after tax), or $0.67 per diluted share, over this period of time, when revised for continuing operations. Costs are expected to be primarily cash expenditures for severance costs and some facility closure costs relating to team reorganizations. Actual costs may vary from these estimates depending on actions taken.

We recorded restructuring charges of $5.3 million ($6.2 million after tax) or $0.02 per diluted share in 2021. The liability related to the Plan was $32.7 million as of the end of the year. We have recorded $244.5 million ($190.0 million after tax), or $0.66 per diluted share, of cumulative restructuring charges under the Plan. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters which continue to be funded from operating activities.

The Plan has delivered $300 million of cumulative cost savings with estimated annual cost savings of $315 million in continuing operations by 2022.

#### Other Restructuring Activities

During 2021, we incurred restructuring charges of $18.7 million ($17.0 million after tax), or $0.06 per diluted share, related to other immaterial restructuring activity. The charges primarily related to severance and asset write-offs.

During 2020, we incurred restructuring charges of $1.8 million ($1.2 million after tax), or less than $0.01 per diluted share, related to other immaterial restructuring plan. The charges are comprised of severance, facility closure costs, including asset disposals, and consulting fees.

During 2019, net restructuring gains related to restructuring plans entered into prior to 2019 were $1.5 million ($1.1 million after tax) or less than $0.01 per diluted share.

The restructuring liability balance for all other restructuring plans excluding Accelerate 2020 and the Institutional Plan were $4.6 million and $5.9 million as of December 31, 2021 and 2020, respectively. The reduction in liability was driven primarily by severance payments. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities. Cash payments during 2021 related to all other restructuring plans excluding the Accelerate 2020 and Institutional Plan were $10.5 million.

### Acquisition and integration related costs

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statements of Income in 2021 include $29.9 million ($23.5 million after tax) or $0.08 per diluted share. Charges are related to the Purolite Corporation (“Purolite”), Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”), and Bioquell PLC (“Bioquell”) acquisitions and consist of integration costs and advisory and legal fees. Acquisition and integration costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2021 include $4.2 million ($3.3 million after tax) or $0.01 per diluted share and are related to the recognition of fair value step-up in the Purolite inventory. In conjunction with its acquisitions, we incurred $0.8 million ($0.6 million after tax), or less than $0.01 per diluted share, of special (gains) and charges reported in interest expense in 2021.

During 2020, acquisition and integration costs reported in special (gains) and charges on the Consolidated Statements of Income include $8.5 million ($6.9 million after tax) or $0.02 per diluted share. Charges are related to CID Lines, Bioquell and the Laboratoires Anios (“Anios”) acquisitions and consist of integration costs and advisory and legal fees. Acquisition and integration costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2020 include $3.9 million ($3.2 million after tax) or $0.01 per diluted share and are related to the recognition of fair value step-up in the CID Lines inventory, severance and the closure of a facility. In conjunction with our acquisitions, we incurred $0.7 million ($0.6 million after tax), or less than $0.01 per diluted share, of special (gains) and charges reported in interest expense in 2020.

During 2019, acquisition and integration costs reported in special (gains) and charges on the Consolidated Statements of Income include $5.6 million ($4.1 million after tax) or $0.01 per diluted share. Charges are primarily related to the Bioquell and Anios acquisitions and consist of integration costs, advisory and legal fees. Acquisition and integration costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2019 include $7.6 million ($5.6 million after tax) or $0.02 per diluted share and are related to recognition of fair value step-up in the Bioquell inventory and facility closure costs. In conjunction with our acquisitions, we incurred $0.2 million ($0.1 million after tax), or less than $0.01 per diluted share, of special (gains) and charges reported in interest expense in 2019.

### Disposal and impairment charges

Disposal and impairment charges reported in special (gains) and charges on the Consolidated Statements of Income include $41.4 million ($41.5 million after tax) or $0.14 per diluted share in the 2020. During 2020, we recorded a $28.6 million ($28.6 million after tax) or $0.10 per diluted share impairment for a minority equity method investment due to the COVID-19 impact on the economic environment and the liquidity of the minority equity method investment. In addition, we recorded charges of $12.8 million ($12.9 million after tax) or $0.04 per diluted share related to the disposal of Holchem Group Limited (“Holchem”) for the loss on sale and related transaction fees during 2020. Further information related to the disposal is included in Note 4.

### COVID-19 activities

Customer demand for sanitizer products surged at the outset of COVID-19. We worked hard to meet the rapidly increasing demand and sold the vast majority of the sanitizer inventory. However, COVID-19 variant-related delays of customer’s reopening and consumer activity resulted in a small portion of excess sanitizer inventory. We have recorded inventory reserves of $60 million during 2021 for excess sanitizer inventory and estimated disposal costs. During 2021 and 2020, we recorded charges of $36.8 million and $57.1 million, respectively, to protect the wages of certain employees directly impacted by the COVID-19 pandemic. We also recorded charges of $16.5 million and $2.4 million related to employee COVID-19 testing and related expenses during 2021 and 2020, respectively. In addition, we received subsidies and government assistance, which were recorded as a special (gain) of ($6.2) million and ($23.4) million during 2021 and 2020, respectively. COVID-19 pandemic charges are recorded in product and equipment cost of sales, service and lease cost of sales, and special (gains) and charges on the Consolidated Statements of Income. Total after tax net charges (gains) related to COVID-19 pandemic were $81.3 million or $0.28 per diluted share and $27.4 million or $0.09 per diluted share during 2021 and 2020, respectively.

### Other operating activities

During 2021, 2020 and 2019, we recorded special charges of $0.3 million ($0.2 million after tax) or less than $0.01 per diluted share, $24.4 million ($16.0 million after tax) or $0.06 per diluted share and $10.5 million ($7.1 million after tax) or $0.02 per diluted share, respectively, recorded in product and equipment cost of sales on the Consolidated Statements of Income primarily related to a Healthcare product recall in Europe.

Other special charges of $18.4 million ($14.1 million after tax) or $0.05 per diluted share in 2021, $34.7 million ($33.9 million after tax) or $0.12 per diluted share recorded in 2020 and $21.4 million ($16.2 million after tax), or $0.06 per diluted share recorded in 2019 relate primarily to a specific legal reserve and related legal charges, partially offset by a litigation settlement in 2019, which are recorded in special (gains) and charges on the Consolidated Statements of Income. We also recorded during 2020 a $7.2 million or $0.02 per diluted share, special charge related to the separation of ChampionX as a tax expense on the Consolidated Statements of Income.

### Other (income) expense

During 2021, we incurred settlement expense recorded in other (income) expense on the Consolidated Statements of Income of $37.2 million ($28.7 million after tax), or $0.10 per diluted share related to U.S. pension plan lump-sum payments to retirees.

During 2020 and 2019, we recorded other expense of $0.4 million ($0.3 million after tax) or less than $0.01 per diluted share and $9.5 million ($7.2 million after tax) or $0.02 per diluted share, respectively, related to pension curtailments and settlements for ChampionX separation and Accelerate 2020. These charges have been included as a component of other (income) expense on the Consolidated Statements of Income.

### Interest expense, net

During 2021 and 2020, we recorded special charges of $32.3 million ($28.4 million after tax) or $0.10 per diluted share and $83.1 million ($64.0 million after tax) or $0.22 per diluted share, respectively, in interest expense on the Consolidated Statements of Income related to debt refinancing charges. In addition, during 2021, 2020 and 2019, an immaterial amount of interest expense was recorded due to acquisition and integration costs.

### Operating Income and Operating Income Margin

| ​ ​ ​ (millions) | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2019 | ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ Percent Change ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ 2020 | ​ ​ ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Reported GAAP operating income | **​** | **​** **$1,598.6** **​** | ​ | ​ $1,395.7 ​ | ​ | ​ $1,845.2 ​ | **​** | ​ | **​** **15%** | ​ | ​ | (24)% |
| Special (gains) and charges |  | **​** **196.5** **​** | ​ | ​ 227.8 ​ | ​ | ​ 158.7 ​ | **​** | ​ | **​** **​** | ​ |  | ​ ​ |
| Impact of Purolite on operating income | **​** | **​** **3.8** **​** | ​ | ​ - ​ | ​ | ​ - ​ | **​** | ​ | **​** **​** **​** | ​ | ​ | ​ ​ |
| Non-GAAP adjusted operating income |  | **​** **1,798.9** **​** | ​ | ​ 1,623.5 ​ | ​ | ​ 2,003.9 ​ | **​** | ​ | **11** **​** | ​ |  | (19) ​ |
| Effect of foreign currency translation |  | **​** **18.9** **​** | ​ | ​ 52.8 ​ | ​ | ​ 37.2 ​ | **​** | ​ | **​** **​** | ​ |  | ​ ​ |
| Non-GAAP adjusted fixed currency operating income | **​** | **​** **$1,817.8** **​** | ​ | ​ $1,676.3 ​ | ​ | ​ $2,041.1 ​ | **​** | ​ | **​** **8%** | ​ | ​ | (18)% |
| ​ | ​ | ​ **​** **​** | ​ | ​ ​ ​ | ​ | ​ ​ ​ | **​** | ​ | ​ **​** **​** | ​ | ​ | ​ ​ |
| (percent) |  | **2021** | ​ | 2020 | ​ | 2019 | ​ | ​ | ​ | ​ | ​ | ​ ​ |
| Reported GAAP operating income margin | **​** | **​** **12.6%** | **​** | ​ 11.8% | ​ | ​ 14.7% | **​** | **​** | ​ ​ ​ | ​ | ​ | ​ ​ |
| Non-GAAP adjusted operating income margin | **​** | **​** **14.1%** | **​** | ​ 13.8% | ​ | ​ 16.0% | **​** | **​** | ​ ​ ​ | ​ | ​ | ​ ​ |
| Non-GAAP adjusted fixed currency operating income margin | **​** | **​** **14.2%** | **​** | ​ 13.8% | ​ | ​ 15.9% | **​** | **​** | ​ ​ ​ | ​ | ​ | ​ ​ |

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by sales.

Our reported operating income increased 15% when comparing 2021 to 2020 primarily driven by increased pricing and higher volume which more than offset significantly higher delivered product costs and supply constraints, including the impact of the Texas Freeze and Hurricane Ida and higher variable compensation compared to last year. Our reported operating income decreased 24% when comparing 2020 to 2019 primarily due to the overall negative impact of the COVID-19 pandemic on results, which yielded lower sales and reduced operating leverage, unfavorable business mix, more than offsetting cost savings, favorable pricing and higher variable compensation. Our reported operating income for 2021, 2020 and 2019 was impacted by special (gains) and charges. Excluding the impact of special (gains) and charges and the impacts of the Purolite transaction, 2021 adjusted operating income increased 11% when compared to 2020 adjusted operating income and 2020 adjusted operating income decreased 19% when compared to 2019 adjusted operating income.

### Other (Income) Expense

| ​ (millions) | ​ | ​ 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ | ​ 2019 | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: |
| Reported GAAP other (income) expense | ​ | **​** | **($33.9)** | **​** | ​ | ​ | ($55.9) | ​ | ​ | ​ | ($77.0) |
| Special (gains) and charges | **​** | **​** | **37.2** | **​** | ​ |  | 0.4 | ​ | ​ |  | 9.5 |
| Non-GAAP adjusted other (income) expense | **​** | **​** | **($71.1)** | **​** | ​ | ​ | ($56.3) | ​ | ​ | ​ | ($86.5) |

Our reported other income was $33.9 million, $55.9 million and $77.0 million in 2021, 2020 and 2019, respectively. Excluding the impact of settlements and curtailments recorded in special (gains) and charges during 2021, 2020 and 2019, our adjusted other income was $71.1 million, $56.3 million and $86.5 million, respectively, reflecting lower interest costs associated with future payments of employee pension obligations.

### Interest Expense, Net

| ​ (millions) | ​ | ​ 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ | ​ 2019 | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: |
| Reported GAAP interest expense, net | ​ | **​** | **$218.3** | **​** | ​ | ​ | $290.2 | ​ | ​ | ​ | $190.7 |
| Special (gains) and charges | **​** | **​** | **33.1** | **​** | ​ |  | 83.8 | ​ | ​ |  | 0.2 |
| Impact of Purolite on interest expense | **​** | **​** | **3.5** | **​** | ​ | ​ | - | ​ | ​ | ​ | - |
| Non-GAAP adjusted interest expense, net | **​** | **​** | **$181.7** | **​** | ​ | ​ | $206.4 | ​ | ​ | ​ | $190.5 |

Our reported net interest expense totaled $218.3 million, $290.2 million and $190.7 million during 2021, 2020 and 2019, respectively.

We incurred $33.1 million ($29.0 million after tax), or $0.10 per diluted share, $83.8 million ($64.6 million after tax), or $0.22 per diluted share and $0.2 million ($0.1 million after tax), or less than $0.01 per diluted share, of interest expense special charges in conjunction with our debt refinancing and acquisitions during 2021, 2020 and 2019, respectively.

Adjusted for special (gains) and charges and the Purolite transaction, the decrease in interest expense when comparing 2021 against 2020 was driven primarily by a reduction in average debt levels and average interest rates. The increase in our 2020 adjusted net interest expense compared to 2019 was driven primarily by higher outstanding debt.

### Provision for Income Taxes

The following table provides a summary of our tax rate:

| ​ (percent) | ​ | ​ ​ 2021 | ​ ​ | ​ ​ 2020 | ​ | ​ ​ 2019 |
| --- | --- | ---: | --- | ---: | --- | ---: |
| Reported GAAP tax rate | **​** | **19.1%** | **​** | 15.2% | **​** | 16.7% |
| Tax rate impact of: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Special (gains) and charges |  | **0.1** **​** | **​** | 0.7 |  | 0.6 |
| Discrete tax items | **​** | **(0.3)** **​** | **​** | 3.8 ​ | **​** | 3.0 ​ |
| Purolite tax impacts |  | **-** **​** | **​** | - |  | - |
| Non-GAAP adjusted tax rate |  | **18.9%** | **​** | 19.7% |  | 20.3% |

Our reported tax rate was 19.1%, 15.2%, and 16.7%, for 2021, 2020 and 2019, respectively. The change in our tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of our historical reported tax rates, as amounts included in our special (gains) and charges are derived from tax jurisdictions with rates that vary from our tax rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future.

We recognized net tax expense of $5.8 million related to discrete tax items during 2021. This included a non-cash deferred tax expense of $25.1 million associated with transferring certain intangible property between affiliates. Share-based compensation excess tax benefit was $29.1 million. The amount of this tax benefit is subject to variation in stock price and award exercises. The remaining discrete tax expense of $9.8 million was primarily related to the filing of federal, state, and foreign tax returns and other income tax adjustments including the impact of changes in tax law, audit settlements and other changes in estimates.

We recognized a total net benefit related to discrete tax items of $55.8 million during 2020. The tax benefit related to share-based compensation excess tax benefit contributed $57.3 million. We recorded changes in reserves in non-U.S. and U.S. jurisdictions due to audit settlements and expiration of statutes of limitations which resulted in a $9.8 million tax benefit. Additionally, we recognized a net tax expense of $11.3 million primarily related to the filing of the prior year federal, state and foreign tax returns and other income tax adjustments.

We recognized total net benefit related to discrete tax items of $57.7 million during 2019. Share-based compensation excess tax benefit contributed $42.3 million in 2019. We recognized $15.6 million tax benefit related to changes in local tax law, which primarily includes $30.4 million benefit due to the passage of the Swiss Tax Reform and AHV Financing Act, a Swiss federal tax law, offset by a tax expense of $10.2 million due to the release of the final Treasury Regulation governing taxation of foreign dividends. We recorded changes in reserves in non-U.S. and U.S. jurisdictions due to audit settlements and statutes of limitations which resulted in a $13.8 million tax benefit. We finalized the 2015 and 2016 IRS audit, which also resulted in discrete tax expense of $11.0 million. The remaining discrete tax expense was primarily related to changes in estimates in non-U.S. jurisdictions.

The change in our adjusted tax rates from 2019 to 2021 was primarily driven by global tax planning projects and geographic income mix. Future comparability of our adjusted tax rate may be impacted by various factors, including but not limited to other changes in global tax rules, further tax planning projects and geographic income mix.

### Net Income from Discontinued Operations, net of tax

| ​ (millions) | ​ | ​ 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ | ​ 2019 | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: |
| Reported GAAP net (loss) income from discontinued operations, net of tax | ​ | **​** | **$-** | **​** | ​ | ​ | ($2,172.5) | ​ | ​ | ​ | $133.3 |
| Adjustments: | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Special (gains) and charges | ​ | **​** | **-** | **​** | ​ | ​ | 2,210.7 | ​ | ​ | ​ | 74.3 |
| Discrete tax net expense (benefit) | **​** | **​** | **-** | **​** | ​ |  | 22.7 | ​ | ​ |  | (0.7) |
| Non-GAAP adjusted net income from discontinued operations, net of tax | **​** | **​** | **$-** | **​** | ​ | ​ | $60.9 | ​ | ​ | ​ | $206.9 |

Special charges reported in discontinued operations consist primarily of ChampionX separation charges.

### Net Income from Continuing Operations Attributable to Ecolab

| ​ ​ ​ (millions) | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ | ​ ​ Percent Change ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ ​ 2020 |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- | --- |
| Reported GAAP net income from continuing operations attributable to Ecolab | **​** | **​** | **$1,129.9** | **​** | ​ | ​ | $967.4 | ​ | ​ | $1,425.6 | **​** | **17%** | **​** | (32)% |
| Adjustments: | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **​** ​ | ​ | ​ ​ |
| Special (gains) and charges, after tax | ​ |  | **213.5** | **​** | ​ |  | 254.1 | ​ |  | 128.3 | ​ | **​** ​ | ​ | ​ ​ |
| Discrete tax net (benefit) expense | ​ | **​** | **5.8** | **​** | ​ | ​ | (55.8) | ​ | ​ | (57.7) | ​ | **​** ​ | ​ | ​ ​ |
| Impact of Purolite on net income | ​ |  | **5.6** | **​** | ​ |  | - | ​ |  | - | ​ | **​** ​ | ​ | ​ ​ |
| Non-GAAP adjusted net income from continuing operations attributable to Ecolab | ​ | **​** | **$1,354.8** | **​** | ​ | ​ | $1,165.7 | ​ | ​ | $1,496.2 | ​ | **16%** | **​** | (22)% |

### Diluted EPS from Continuing Operations

| ​ ​ ​ (dollars) | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ | ​ ​ Percent Change ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ ​ 2020 |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- | --- |
| Reported GAAP diluted EPS from continuing operations | **​** | **​** | **$ 3.91** | **​** | ​ | ​ | $ 3.33 | ​ | ​ | $ 4.87 | **​** | **17%** | **​** | (32)% |
| Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ ​ | ​ | ​ ​ |
| Special (gains) and charges, after tax | **​** |  | **0.74** | **​** | ​ |  | 0.88 | ​ |  | 0.45 | **​** | ​ ​ | ​ | ​ ​ |
| Discrete tax net (benefit) expense | ​ |  | **0.02** | **​** | ​ |  | (0.19) | ​ |  | (0.20) | ​ | ​ ​ | ​ | ​ ​ |
| Impact of Purolite on diluted EPS | ​ | **​** | **0.02** | **​** | ​ | ​ | - | ​ | ​ | - | ​ | ​ ​ | ​ | ​ ​ |
| Non-GAAP adjusted diluted EPS from continuing operations | ​ | **​** | **$4.69** | **​** | ​ | ​ | $ 4.02 | ​ | ​ | $ 5.12 | ​ | **17%** | **​** | (21)% |

Per share amounts do not necessarily sum due to rounding.

Currency translation had an favorable $0.11 impact on reported and adjusted diluted EPS when comparing 2021 to 2020 and unfavorable $0.05 impact when comparing 2020 to 2019.

### SEGMENT PERFORMANCE

The non-U.S. dollar functional currency international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates established by management for 2021. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as “effect of foreign currency translation” in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2. Additional information about our reportable segments is included in Note 19.

Fixed currency net sales and operating income for 2021, 2020 and 2019 for our reportable segments are shown in the following tables.

| ​ Net Sales ​ (millions) | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ ​ ​ Percent Change ​ ​ ​ ​ ​ 2021 ​ 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | ---: |
| Global Industrial | **​** | **​** **$6,304.9** **​** |  | ​ $6,048.2 |  | ​ $6,087.9 | **​** | **4%** **​** (1)% |
| Global Institutional & Specialty |  | **​** **3,978.2** **​** | ​ | 3,629.0 | ​ | 4,477.2 |  | **10** ​ ​ (19) ​ |
| Global Healthcare & Life Sciences | **​** | **​** **1,195.4** **​** | ​ | ​ 1,241.1 | ​ | ​ 1,017.6 | **​** | **(4)** ​ ​ 22 ​ |
| Other |  | **​** **1,226.9** **​** | ​ | 1,103.4 | ​ | 1,220.5 |  | **11** ​ ​ (10) ​ |
| Corporate | **​** | **​** **139.4** **​** | ​ | ​ 100.6 | ​ | ​ - | **​** | **39** ​ ​ 100 ​ |
| Subtotal at fixed currency |  | **​** **12,844.8** **​** | ​ | 12,122.3 | ​ | 12,803.2 |  | **6** ​ ​ (5) ​ |
| Effect of foreign currency translation |  | **​** **(111.7)** **​** | ​ | (332.1) | ​ | (241.2) |  | **​** ​ ​ ​ ​ |
| Total reported net sales |  | **​** **$12,733.1** **​** | ​ | ​ $11,790.2 | ​ | ​ $12,562.0 |  | **8%** **​** (6)% |
| ​ | ​ | ​ ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | **​** **​** | ​ | ​ ​ | ​ | ​ ​ | **​** | Percent Change |
| ​ | **​** | **​** **​** **​** | ​ | ​ ​ | ​ | ​ ​ | **​** | ​ ​ ​ ​ ​ |
| (millions) |  | **2021** |  | 2020 |  | 2019 |  | **2021** **​** 2020 |
| Global Industrial | **​** | **​** **$1,031.0** **​** |  | ​ $1,123.1 |  | ​ $921.3 | **​** | **(8)%** **​** 22% |
| Global Institutional & Specialty |  | **​** **556.9** **​** | ​ | 324.0 | ​ | 945.8 |  | **72** ​ ​ (66) ​ |
| Global Healthcare & Life Sciences | **​** | **​** **160.9** **​** | ​ | ​ 218.3 | ​ | ​ 129.2 | **​** | **(26)** ​ ​ 69 ​ |
| Other |  | **​** **187.3** **​** | ​ | 132.8 | ​ | 169.7 |  | **41** ​ ​ (22) ​ |
| Corporate |  | **​** **(318.6)** **​** | ​ | (349.7) | ​ | (283.6) |  | **(9)** ​ ​ 23 ​ |
| Subtotal at fixed currency |  | **​** **1,617.5** **​** | ​ | 1,448.5 | ​ | 1,882.4 |  | **12** ​ ​ (23) ​ |
| Effect of foreign currency translation |  | **​** **(18.9)** **​** | ​ | (52.8) | ​ | (37.2) |  | **​** ​ ​ ​ ​ |
| Total reported operating income |  | **​** **$1,598.6** **​** | ​ | ​ $1,395.7 | ​ | ​ $1,845.2 |  | **15%** **​** (24)% |

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments.

| ​ ​ ​ Net Sales (millions) | ​ ​ ​ ​ | ​ ​ ​ ​ ​ Year ended December 31 2021 Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted | ​ ​ ​ | ​ ​ ​ ​ ​ 2020 Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| --- | --- | ---: | --- | ---: |
| Global Industrial | **​** | **$6,304.9** **​** **(65.9)** **​** **$6,239.0** | ​ | $6,048.2 ​ (37.1) ​ $6,011.1 |
| Global Institutional & Specialty |  | **3,978.2** **​** **(14.2)** **​** **3,964.0** | ​ | 3,629.0 ​ - ​ 3,629.0 |
| Global Healthcare & Life Sciences | **​** | **1,195.4** **​** **(44.5)** **​** **1,150.9** | ​ | 1,241.1 ​ (1.2) ​ 1,239.9 |
| Other |  | **1,226.9** **​** **-** **​** **1,226.9** | ​ | 1,103.4 ​ - ​ 1,103.4 |
| Corporate | **​** | **139.4** **​** **(139.4)** **​** **-** | ​ | 100.6 ​ (100.6) ​ - |
| Subtotal at fixed currency |  | **12,844.8** **​** **(264.0)** **​** **12,580.8** | ​ | 12,122.3 ​ (138.9) ​ 11,983.4 |
| Effect of foreign currency translation |  | **(111.7)** **​** ​ **​** ​ | ​ | (332.1) ​ ​ ​ ​ |
| Total reported net sales |  | **$12,733.1** **​** ​ **​** ​ | ​ | $11,790.2 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ | ​ | ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | **2021** | ​ | 2020 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted | ​ | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$1,031.0** **​** **(3.4)** **​** **$1,027.6** | ​ | $1,123.1 ​ (2.6) ​ $1,120.5 |
| Global Institutional & Specialty |  | **556.9** **​** **2.2** **​** **559.1** | ​ | 324.0 ​ - ​ 324.0 |
| Global Healthcare & Life Sciences |  | **160.9** **​** **10.2** **​** **171.1** | ​ | 218.3 ​ (0.2) ​ 218.1 |
| Other | **​** | **187.3** **​** **-** **​** **187.3** | ​ | 132.8 ​ - ​ 132.8 |
| Corporate |  | **(122.1)** **​** **-** **​** **(122.1)** | ​ | (121.9) ​ - ​ (121.9) |
| Non-GAAP adjusted fixed currency operating income |  | **1,814.0** **​** **9.0** **​** **1,823.0** | ​ | 1,676.3 ​ (2.8) ​ 1,673.5 |
| Special (gains) and charges |  | **196.5** **​** **​** **​** **​** | ​ | 227.8 ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **1,617.5** **​** **​** **​** **​** | ​ | 1,448.5 ​ ​ ​ ​ |
| Effect of foreign currency translation |  | **(18.9)** **​** **​** **​** **​** | ​ | (52.8) ​ ​ ​ ​ |
| Total reported operating income |  | **$1,598.6** **​** **​** **​** **​** | ​ | $1,395.7 ​ ​ ​ ​ |

39

### Global Industrial

| ​ ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$6,304.9** ​ | ​ | ​ | $6,048.2 ​ | ​ | ​ | $6,087.9 ​ |
| Sales at public currency (millions) | **​** | **​** | **6,237.8** ​ | ​ | ​ | 5,867.1 ​ | ​ | ​ | 5,978.8 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Volume | **​** |  | **2%** | **​** | ​ | (3)% | ​ | ​ | ​ ​ |
| Price changes | **​** |  | **2%** | **​** | ​ | 2% | ​ | ​ | ​ ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **4%** | **​** | ​ | (1)% | ​ | ​ | ​ ​ |
| Acquisitions and divestitures | **​** |  | **-%** | **​** | ​ | 1% | ​ | ​ | ​ ​ |
| Fixed currency sales change | **​** |  | **4%** | **​** | ​ | (1)% | ​ | ​ | ​ ​ |
| Foreign currency translation | **​** | **​** | **2%** | **​** | ​ | (1)% | ​ | ​ | ​ ​ |
| Public currency sales change | **​** |  | **6%** | **​** | ​ | (2)% | ​ | ​ | ​ ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$1,031.0** ​ | ​ | ​ | $1,123.1 ​ | ​ | ​ | $921.3 ​ |
| Operating income at public currency (millions) | **​** | **​** | **1,016.3** ​ | ​ | ​ | 1,086.8 ​ | ​ | ​ | 901.6 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Fixed currency operating income change | **​** | **​** | **(8)%** | **​** | ​ | 22% | ​ | ​ | ​ ​ |
| Fixed currency operating income margin | **​** |  | **16.4%** | **​** |  | 18.6% | ​ |  | 15.1% |
| Acquisition adjusted fixed currency operating income change | **​** |  | **(8)%** | **​** |  | 22% | ​ | ​ | ​ ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **16.5%** | **​** |  | 18.6% | ​ | ​ | \* ​ |
| Public currency operating income change | ​ | ​ | **(6)%** | **​** | ​ | 21% | ​ | ​ | ​ ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |

\* Not meaningful

Amounts do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Global Industrial increased in 2021 as strong growth in Paper and Water, led by recovering market conditions, strong pricing and new business wins, along with a good growth in Food & Beverage, were offset by a decrease in Downstream sales growth. The 2020 sales decrease was impacted by regional declines in North America and Asia Pacific, partially offset by growth in all other regions.

At an operating segment level, ***Water*** fixed currency sales increased 6% in 2021 as strong new business wins and accelerating pricing leveraged recovering markets. Water fixed currency sales decreased 2% in 2020. Light industry water treatment sales had solid growth in 2021 and modest growth in 2020 led by good gains in food & beverage, light manufacturing and data centers. Heavy industry sales recorded a strong increase in 2021 driven by primary metals and were moderately lower in 2020, impacted by lower end market demand. ***Food & Beverage*** fixed currency sales increased 3% (2% acquisition adjusted) in 2021 primarily reflecting accelerating pricing, recovering markets and new business wins. Globally, we realized strong growth in beverage, brewing and modest growth in dairy. Fixed currency sales increased 5% (3% acquisition adjusted) in 2020, as share gains and pricing more than offset generally flat industry trends. ***Downstream*** fixed currency sales decreased 3% and 8% in 2021 and 2020, respectively, due to lower demand from COVID and impacts from the Texas freeze and Hurricane Ida impacts in 2021, while substantial reductions in transportation fuel demand and additive use hurt 2020 results. ***Paper*** fixed currency sales increased 11% in 2021 driven by increased pricing, strong new business wins, and increased ecommerce activity. Fixed currency sales were flat in 2020 despite softer industrial containerboard market conditions which reduced volumes in major regions.

### Operating Income

Fixed currency operating income and fixed currency operating income margins for Global Industrial decreased in 2021 and increased in 2020 when compared to prior periods.

Acquisition adjusted fixed currency operating income margins decreased 2.1 percentage points in 2021 compared to 2020, as the 1.8 percentage point positive impact from accelerating pricing was more than offset by the 3.4 percentage point negative impact of significantly higher delivered product costs and supply constraints, including the impact of Texas Freeze and Hurricane Ida. Acquisition adjusted fixed currency operating income margins increased in 2020, as the favorable impacts of cost savings, pricing, lower delivered product costs and lower variable compensation more than offset the negative impact of lower volume.

### Global Institutional & Specialty

| ​ ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$3,978.2** ​ | ​ | ​ | $3,629.0 ​ | ​ | ​ | $4,477.2 ​ |
| Sales at public currency (millions) | **​** | **​** | **3,955.9** ​ | ​ | ​ | 3,562.5 ​ | ​ | ​ | 4,416.1 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Volume | **​** |  | **7%** | **​** | ​ | (21)% | ​ | ​ | ​ ​ |
| Price changes | **​** |  | **2%** | **​** | ​ | 2% | ​ | ​ | ​ ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **9%** | **​** | ​ | (20)% | ​ | ​ | ​ ​ |
| Acquisitions and divestitures | **​** |  | **-%** | **​** | ​ | 1% | ​ | ​ | ​ ​ |
| Fixed currency sales change | **​** |  | **10%** | **​** | ​ | (19)% | ​ | ​ | ​ ​ |
| Foreign currency translation | **​** | **​** | **1%** | **​** | ​ | -% | ​ | ​ | ​ ​ |
| Public currency sales change | **​** |  | **11%** | **​** | ​ | (19)% | ​ | ​ | ​ ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$556.9** ​ | ​ | ​ | $324.0 ​ | ​ | ​ | $945.8 ​ |
| Operating income at public currency (millions) | **​** | **​** | **554.7** ​ | ​ | ​ | 320.1 ​ | ​ | ​ | 936.8 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Fixed currency operating income change | **​** | **​** | **72%** | **​** | ​ | (66)% | ​ | ​ | ​ ​ |
| Fixed currency operating income margin | **​** |  | **14.0%** | **​** |  | 8.9% | ​ |  | 21.1% |
| Acquisition adjusted fixed currency operating income change | **​** |  | **73%** | **​** |  | (66)% | ​ | ​ | ​ ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **14.1%** | **​** |  | 8.9% | ​ | ​ | \* ​ |
| Public currency operating income change | ​ | ​ | **73%** | **​** | ​ | (66)% | ​ | ​ | ​ ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |

\* Not meaningful

Amounts do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Global Institutional & Specialty increased in 2021 driven by strong growth in the Institutional operating segment reflecting recovering markets, new business wins including gains from the Ecolab Science Certified programs, innovation and accelerating pricing and decreased in 2020 driven by a significant decline in the Institutional business due to the impact of the COVID-19 pandemic.

At an operating segment level, ***Institutional*** fixed currency sales increased 15% in 2021, driven by strong growth in the Institutional operating segment reflecting recovering markets in the U.S. and Europe, new business wins including gains from the Ecolab Science Certified programs, innovation and accelerating pricing. Fixed currency sales decreased 27% in 2020, reflecting strong hand and surface hygiene sales that were more than offset by the negative effects of mandated reductions for in-unit dining and domestic and international travel that significantly reduced foot traffic at full-service restaurants, occupancy rates at hotels and customer visits to other entertainment facilities through the year. ***Specialty*** fixed currency sales decreased 3% in 2021, as modest quickservice sales growth were more than offset by lower food retail sales. Quickservice sales showed a modest gain as new business wins more than offset impacts of COVID-19 restrictions and labor shortages. Food retail sales declined versus the strong sanitizer demand in 2020 and customer labor shortages that has resulted in reduced in-store services and associated product usage. Fixed currency sales increased 8% (5% acquisition adjusted) in 2020, as strong food retail sales growth, benefiting from continued expanded cleaning protocols and frequency in the grocery stores in response to the COVID-19 pandemic and new customer additions, was partially offset by moderately lower quickservice sales, which saw strong hand and surface sanitizer sales more than offset by COVID-19 pandemic related impacts on restaurant volumes.

### Operating Income

Fixed currency operating income for our Global Institutional & Specialty segment increased in 2021 and decreased in 2020 when compared to prior periods. Fixed currency operating income margins increased in 2021 after decreasing in 2020.

Acquisition adjusted fixed currency operating income margins increased 5.2 percentage points during 2021, as the 6.9 percentage point positive impact from higher volume, accelerating pricing, and favorable mix more than offset the 2.4 percentage point negative impact of the comparison to lower variable compensation last year and higher delivered product costs. Acquisition adjusted fixed currency operating income margins decreased during 2020 as margins were negatively impacted from volume declines, unfavorable mix and higher bad debt expense, which more than offset the positive impact of cost savings.

### Global Healthcare & Life Sciences

| ​ ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$1,195.4** ​ | ​ | ​ | $1,241.1 ​ | ​ | ​ | $1,017.6 ​ |
| Sales at public currency (millions) | **​** | **​** | **1,181.6** ​ | ​ | ​ | 1,185.5 ​ | ​ | ​ | 974.1 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Volume | **​** |  | **(9)%** | **​** | ​ | 18% | ​ | ​ | ​ ​ |
| Price changes | **​** |  | **2%** | **​** | ​ | 1% | ​ | ​ | ​ ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **(7)%** | **​** | ​ | 19% | ​ | ​ | ​ ​ |
| Acquisitions and divestitures | **​** |  | **3%** | **​** | ​ | 2% | ​ | ​ | ​ ​ |
| Fixed currency sales change | **​** |  | **(4)%** | **​** | ​ | 21% | ​ | ​ | ​ ​ |
| Foreign currency translation | **​** | **​** | **4%** | **​** | ​ | -% | ​ | ​ | ​ ​ |
| Public currency sales change | **​** |  | **0%** | **​** | ​ | 21% | ​ | ​ | ​ ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$160.9** ​ | ​ | ​ | $218.3 ​ | ​ | ​ | $129.2 ​ |
| Operating income at public currency (millions) | **​** | **​** | **159.2** ​ | ​ | ​ | 205.7 ​ | ​ | ​ | 121.6 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Fixed currency operating income change | **​** | **​** | **(26)%** | **​** | ​ | 69% | ​ | ​ | ​ ​ |
| Fixed currency operating income margin | **​** |  | **13.5%** | **​** |  | 17.6% | ​ |  | 12.7% |
| Acquisition adjusted fixed currency operating income change | **​** |  | **(22)%** | **​** |  | 67% | ​ | ​ | ​ ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **14.9%** | **​** |  | 17.6% | ​ | ​ | \* ​ |
| Public currency operating income change | ​ | ​ | **(23)%** | **​** | ​ | 69% | ​ | ​ | ​ ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |

\* Not meaningful

Amounts do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales decreased for Global Healthcare & Life Sciences in 2021 compared to a strong 2020 year when sales benefited from strong COVID-19 related demand and increased in 2020 as growth was driven by volume and pricing gains.

At an operating segment level, ***Healthcare*** fixed currency sales decreased 5% (8% acquisition adjusted) in 2021 reflecting the comparison against strong 2020 COVID-19 related hand and surface disinfection sales as well as softer elective surgical procedures activity in 2021 due to the rise in COVID variants during the year. Fixed currency sales increased 18% (16% acquisition adjusted) in 2020. Strong COVID-19 pandemic related hand and surface disinfection sales growth more than offset the unfavorable effects of delayed elective surgical procedures. ***Life Sciences*** fixed currency sales decreased 5% (4% acquisition adjusted) in 2021 as accelerating pricing was more than offset by volume declines versus the very strong 2020 driven by extraordinary COVID-19 demand last year. Fixed currency sales increased 35% in 2020, led by strong demand for biodecontamination units, business wins and pricing in our cleaning and disinfection programs for both the pharmaceutical and personal care markets, with strong growth in Europe and moderate North America gains.

### Operating Income

Fixed currency operating income for our Global Healthcare & Life Sciences segment decreased in 2021 and increased in 2020 when compared to prior periods. Fixed currency operating income margins decreased in 2021 and increased in 2020.

Acquisition adjusted fixed currency operating income margins decreased 2.7 percentage points in 2021, as the 1.8 percentage point positive impact from accelerating pricing was more than offset by the 3.5 percentage point negative impact of volume declines due to strong comparison against last year. Acquisition adjusted fixed currency operating income margins increased in 2020 driven by strong volume gains, reduced discretionary spending and pricing, partially offset by negative impact of higher delivered product costs.

### Other

| ​ ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$1,226.9** ​ | ​ | ​ | $1,103.4 ​ | ​ | ​ | $1,220.5 ​ |
| Sales at public currency (millions) | **​** | **​** | **1,218.6** ​ | ​ | ​ | 1,075.1 ​ | ​ | ​ | 1,193.0 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Volume | **​** |  | **9%** | **​** | ​ | (11)% | ​ | ​ | ​ ​ |
| Price changes | **​** |  | **2%** | **​** | ​ | 2% | ​ | ​ | ​ ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **11%** | **​** | ​ | (10)% | ​ | ​ | ​ ​ |
| Acquisitions and divestitures | **​** |  | **-%** | **​** | ​ | -% | ​ | ​ | ​ ​ |
| Fixed currency sales change | **​** |  | **11%** | **​** | ​ | (10)% | ​ | ​ | ​ ​ |
| Foreign currency translation | **​** | **​** | **2%** | **​** | ​ | -% | ​ | ​ | ​ ​ |
| Public currency sales change | **​** |  | **13%** | **​** | ​ | (10)% | ​ | ​ | ​ ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$187.3** ​ | ​ | ​ | $132.8 ​ | ​ | ​ | $169.7 ​ |
| Operating income at public currency (millions) | **​** | **​** | **186.2** ​ | ​ | ​ | 130.2 ​ | ​ | ​ | 165.2 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Fixed currency operating income change | **​** | **​** | **41%** | **​** | ​ | (22)% | ​ | ​ | ​ ​ |
| Fixed currency operating income margin | **​** |  | **15.3%** | **​** |  | 12.0% | ​ |  | 13.9% |
| Acquisition adjusted fixed currency operating income change | **​** |  | **41%** | **​** |  | (21)% | ​ | ​ | ​ ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **15.3%** | **​** |  | 12.0% | ​ | ​ | \* ​ |
| Public currency operating income change | ​ | ​ | **43%** | **​** | ​ | (21)% | ​ | ​ | ​ ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |

\* Not meaningful

Amounts do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Other increased in 2021 led by strong growth in Pest Elimination as it benefited from new business wins and a recovering market. Fixed currency sales decreased in 2020 with declines in sales results mostly impacting North America and Europe.

At an operating segment level, ***Pest Elimination*** fixed currency sales increased 11% in 2021 reflecting strong growth in food and beverage plants, restaurants and hospitality markets. Fixed currency sales decreased 2% in 2020 with sales growth in food and beverage plants, grocery stores and healthcare facilities offset by the impact of lower restaurant and hospitality volumes impacted by the COVID-19 pandemic due to partial or full customer closures along with limited vendor access. ***Textile Care*** fixed currency sales increased 10% in 2021 and decreased 27% in 2020. ***Colloidal Technologies Group*** fixed currency sales increased 16% in 2021 and decreased 18% in 2020.

### Operating Income

Fixed currency operating income in Other increased in 2021 and decreased in 2020 as compared to the prior year. Fixed currency operating income margins increased in 2021 and declined in 2020.

Acquisition adjusted fixed currency operating income margins in Other increased 3.3 percentage points in 2021, as the 4.4 percentage point positive impact from higher volume and increased pricing more than offset the 1.1 percentage point negative impact of the comparison to lower variable compensation last year. Acquisition adjusted fixed currency operating income margins in Other decreased in 2020 reflecting lower volume and unfavorable mix negatively impacted margins, which more than offset positive impact of cost savings and pricing.

### Corporate

Consistent with our internal management reporting, Corporate amounts in the table on page 39 include sales to ChampionX in accordance with the long-term supply agreement entered into with the Transaction post-separation, as discussed in Note 5, intangible asset amortization specifically from the Nalco merger and special (gains) and charges that are not allocated to our reportable segments. Items included within special (gains) and charges are shown in the table on page 33.

### FINANCIAL POSITION, CASH FLOW AND LIQUIDITY

### Financial Position

Total assets were $21.2 billion as of December 31, 2021, compared to total assets of $18.1 billion as of December 31, 2020.

Total liabilities were $14.0 billion as of December 31, 2021, compared to total liabilities of $11.9 billion as of December 31, 2020. Total debt was $8.8 billion as of December 31, 2021 and $6.7 billion as of December 31, 2020. See further discussion of our debt activity within the “Liquidity and Capital Resources” section of this MD&A.

Our net debt to EBITDA is shown in the following table. EBITDA is a non-GAAP measure discussed further in the “Non-GAAP Financial Measures” section of this MD&A.

| ​ ​ (ratio) | ​ ​ ​ | ​ 2021 ​ | ​ ​ | ​ ​ | ​ ​ ​ | ​ 2020 ​ | ​ ​ | ​ ​ | ​ ​ ​ | ​ 2019 ​ | ​ ​ | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Net debt to EBITDA |  | **​** | **3.4** | **​** |  | ​ | 2.4 | ​ |  | ​ | 2.3 | ​ |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| (millions) |  | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Total debt | **​** | **​** | **$8,758.2** | **​** | ​ | ​ | $6,686.6 | ​ | ​ | ​ | $6,353.6 | ​ |
| Cash | **​** |  | **359.9** | **​** | ​ | ​ | 1,260.2 | ​ | ​ | ​ | 118.8 | ​ |
| Net debt | **​** | **​** | **$8,398.3** | **​** | ​ | ​ | $5,426.4 | ​ | ​ | ​ | $6,234.8 | ​ |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Net income including noncontrolling interest | ​ | **​** | **$1,144.0** | **​** | ​ | ​ | $984.8 | ​ | ​ | ​ | $1,442.9 | ​ |
| Provision for income taxes | **​** |  | **270.2** | **​** | ​ | ​ | 176.6 | ​ | ​ | ​ | 288.6 | ​ |
| Interest expense, net | **​** |  | **218.3** | **​** | ​ | ​ | 290.2 | ​ | ​ | ​ | 190.7 | ​ |
| Depreciation | **​** |  | **604.4** | **​** | ​ | ​ | 594.3 | ​ | ​ | ​ | 569.1 | ​ |
| Amortization | **​** |  | **238.7** | **​** | ​ | ​ | 218.4 | ​ | ​ | ​ | 206.2 | ​ |
| EBITDA | **​** |  | **$2,475.6** | **​** | ​ | ​ | $2,264.3 | ​ | ​ | ​ | $2,697.5 | ​ |

### Cash Flows

### Operating Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ Dollar Change ​ 2021 | ​ ​ | ​ ​ | ​ ​ | ​ ​ 2020 | ​ ​ | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Cash provided by operating activities | ​ | **​** | **$2,061.9** | ​ | ​ | ​ | $1,741.8 | ​ | ​ | ​ | $2,046.7 | ​ | ​ | **​** | **$320.1** | **​** | ​ | ​ | ($304.9) | ​ |

We continue to generate strong cash flow from operations, amidst the COVID-19 pandemic, allowing us to fund our ongoing operations, acquisitions, investments in the business and pension obligations along with returning cash to our shareholders through dividend payments and share repurchases.

Cash provided by operating activities increased $320 million in 2021 compared to 2020, driven primarily by $159 million in increased net income, $94 million in higher tax expense accruals associated with higher income, and an increase in accruals for variable compensation, partially offset by $83 million of increased investment in working capital. Cash provided by operating activities decreased $305 million in 2020 compared to 2019, driven primarily by $458 million of lower net income due to the impact of COVID-19, partially offset by $160 million of improvement in working capital.

The impact on operating cash flows of pension and postretirement plan contributions, cash activity related to restructuring, cash paid for income taxes and cash paid for interest, are shown in the following table:

| ​ ​ ​ (millions) | ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ ​ | ​ Dollar Change ​ 2021 | ​ ​ | ​ ​ | ​ ​ 2020 | ​ ​ | ​ ​ |
| --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Pensions and postretirement plan contributions |  | **$60.2** | ​ | ​ | ​ | $70.7 | ​ |  | ​ | $186.0 | ​ | **​** | **($10.5)** | **​** |  | ​ | ($115.3) | ​ |
| Restructuring payments | **​** | **78.3** | ​ | ​ |  | 71.1 | ​ | ​ |  | 82.5 | ​ | **​** | **7.2** | **​** | ​ |  | (11.4) | ​ |
| Income tax payments | **​** | **275.7** | ​ | ​ |  | 366.9 | ​ | ​ |  | 337.4 | ​ | **​** | **(91.2)** | **​** | ​ |  | 29.5 | ​ |
| Interest payments | **​** | **208.7** | ​ | ​ |  | 262.5 | ​ | ​ |  | 189.4 | ​ | **​** | **(53.8)** | **​** | ​ |  | 73.1 | ​ |

### Investing Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ Dollar Change ​ 2021 | ​ ​ | ​ ​ | ​ ​ | ​ ​ 2020 | ​ ​ | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Cash used for investing activities | ​ | **​** | **($4,579.7)** | ​ | ​ | ​ | ($857.7) | ​ | ​ | ​ | ($1,129.6) | ​ | ​ | **​** | **($3,722.0)** | **​** | ​ | ​ | $271.9 | ​ |

Cash used for investing activities is primarily impacted by the timing of business acquisitions and dispositions as well as from capital investments in the business.

Total cash paid for acquisitions, net of cash acquired and net of cash received from dispositions, in 2021, 2020 and 2019 was $3,924 million, $371 million and $385 million, respectively. Our acquisitions and divestitures are discussed further in Note 4. We continue to target strategic business acquisitions which complement our growth strategy and expect to continue to make capital investments and acquisitions in the future to support our long-term growth.

We continue to make capital investments in the business, including merchandising and customer equipment and manufacturing facilities. Total capital expenditures were $643 million, $489 million and $731 million in 2021, 2020 and 2019, respectively.

### Financing Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ Dollar Change ​ 2021 | ​ ​ | ​ ​ | ​ ​ | ​ ​ 2020 | ​ ​ | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Cash provided by (used for) financing activities | ​ | **​** | **$1,603.2** | ​ | ​ | ​ | ($340.2) | ​ | ​ | ​ | ($1,346.6) | ​ | ​ | **​** | **$1,943.4** | **​** | ​ | ​ | $1,006.4 | ​ |

Our cash flows from financing activities primarily reflect the issuances and repayment of debt, common stock repurchases, proceeds from common stock issuances related to our equity incentive programs and dividend payments.

We issued $2,800 million par value and received $2,775 million in proceeds of long-term debt and repaid $900 million of long-term debt in 2021. We issued $1,850 million par value and received $1,856 million in proceeds of long-term debt and repaid $1,570 million of long-term debt in 2020. We repaid $401 million of long-term debt in 2019. The proceeds received from the debt issuances were used for the Purolite acquisition, repayment of outstanding debt, repayment of commercial paper and general corporate purposes. In addition, we issued $394 million of commercial paper and notes payable in 2021 and repaid $66 million and $252 million in 2020 and 2019, respectively.

Shares are repurchased for the purpose of partially offsetting the dilutive effect of our equity compensation plans and stock issued in acquisitions, to manage our capital structure and to efficiently return capital to shareholders. We repurchased a total of $107 million, $146 million, and $354 million of shares in 2021, 2020 and 2019, respectively.

The impact on financing cash flows of commercial paper and notes payable repayments, long-term debt borrowings and long-term debt repayments, are shown in the following table:

| ​ ​ ​ (millions) | ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ 2021 | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ 2020 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ 2019 | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ ​ | ​ Dollar Change ​ 2021 | ​ ​ | ​ ​ | ​ ​ 2020 | ​ ​ | ​ ​ |
| --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Net issuances (repayments) of commercial paper and notes payable | **​** | **$393.6** | ​ | ​ | ​ | ($65.5) | ​ |  | ​ | ($252.0) | ​ | **​** | **$459.1** | **​** |  | ​ | $186.5 | ​ |
| Long-term debt borrowings | **​** | **2,775.0** | ​ | ​ |  | 1,855.9 | ​ | ​ |  | — | ​ | **​** | **919.1** | **​** | ​ |  | 1,855.9 | ​ |
| Long-term debt repayments | **​** | **(1,017.9)** | ​ | ​ |  | (1,570.0) | ​ | ​ |  | (400.6) | ​ | **​** | **552.1** | **​** | ​ |  | (1,169.4) | ​ |

In December 2021, we increased our quarterly dividend rate by 6%. This represents the 30th consecutive year we have increased our dividend. We have paid dividends on our common stock for 85 consecutive years. We paid dividends of $566 million, $561 million and $553 million in 2021, 2020 and 2019, respectively. Cash dividends declared per share of common stock, by quarter, for each of the last three years were as follows:

| ​ ​ ​ | ​ ​ ​ | ​ First Quarter | ​ | ​ | ​ ​ ​ | ​ Second Quarter | ​ | ​ | ​ ​ ​ | ​ Third Quarter | ​ | ​ | ​ ​ ​ | ​ Fourth Quarter | ​ | ​ | ​ ​ ​ | ​ Year | ​ ​ | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| **2021** | **​** | **​** | **$0.48** | **​** | **​** | **​** | **$0.48** | **​** | **​** | **​** | **$0.48** | **​** | **​** | **​** | **$0.51** | **​** | **​** | **​** | **$1.95** | **​** |
| 2020 | ​ |  | $0.47 | ​ | ​ | ​ | $0.47 | ​ | ​ | ​ | $0.47 | ​ | ​ | ​ | $0.48 | ​ | ​ | ​ | $1.89 | ​ |
| 2019 | ​ |  | $0.46 | ​ | ​ | ​ | $0.46 | ​ | ​ | ​ | $0.46 | ​ | ​ | ​ | $0.47 | ​ | ​ | ​ | $1.85 | ​ |

### Liquidity and Capital Resources

We currently expect to fund all of our cash requirements which are reasonably foreseeable for the next twelve months, including scheduled debt repayments, new investments in the business, share repurchases, dividend payments, possible business acquisitions and pension and postretirement contributions with cash from operating activities, and as needed, additional short-term and/or long-term borrowings. We continue to expect our operating cash flow to remain strong.

As of December 31, 2021, we had $360 million of cash and cash equivalents on hand, of which $181 million was held outside of the U.S. As of December 31, 2020, we had $1,260 million of cash and cash equivalents on hand, of which $59 million was held outside of the U.S. We will continue to evaluate our cash position in light of future developments.

As of December 31, 2021, we had a $2.0 billion multi-year credit facility, which expires in April 2026. The credit facility has been established with a diverse syndicate of banks and supports our U.S. and Euro commercial paper programs. The maximum aggregate amount of commercial paper that may be issued under our U.S. commercial paper program and our Euro commercial paper program may not exceed $2.0 billion. At year end, we had $400 million outstanding commercial paper under our U.S. program and no commercial paper outstanding on our Euro program. There were no borrowings under our credit facility as of December 31, 2021 or 2020. As of December 31, 2021, both programs were rated A-2 by Standard & Poor’s, P-2 by Moody’s and F-1 by Fitch.

We had a $305 million term credit agreement which we drew on and repaid $303 million during the second quarter of 2020. The credit agreement expired in June 2020.

Additionally, we have uncommitted credit lines with major international banks and financial institutions. These credit lines support our daily global funding needs, primarily our global cash pooling structures. We have $118 million of bank supported letters of credit, surety bonds and guarantees outstanding in support of our commercial business transactions. We do not have any other significant unconditional purchase obligations or commercial commitments.

As of December 31, 2021, Standard & Poor’s and Fitch both rated our long-term credit at A- (stable outlook) and Moody’s rated our long-term credit at A3 (stable outlook). A reduction in our credit ratings could limit or preclude our ability to issue commercial paper under our current programs or could also adversely affect our ability to renew existing, or negotiate new, credit facilities in the future and could increase the cost of these facilities.

We are in compliance with our debt covenants and other requirements of our credit agreements and indentures.

A schedule of our various obligations as of December 31, 2021 are summarized in the following table:

| ​ ​ ​ ​ (millions) | ​ ​ ​ ​ ​ | ​ ​ ​ ​ Total | ​ ​ ​ ​ | ​ ​ ​ ​ ​ | ​ Payments Due by Period Less Than 1 Year | ​ | ​ ​ ​ ​ | ​ ​ 2-3 Years | ​ ​ | ​ ​ ​ ​ | ​ ​ 4-5 Years | ​ ​ | ​ ​ ​ ​ | ​ More Than 5 Years | ​ | ​ |
| --- | --- | --- | ---: | --- | --- | ---: | --- | --- | ---: | --- | --- | ---: | --- | --- | ---: | --- |
| Notes payable | ​ | ​ | $ 8 | ​ | ​ | $ 8 |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| One-time transition tax | ​ |  | 83 | ​ |  | ​ | ​ |  | 13 | ​ | ​ | 70 | ​ |  | ​ | ​ |
| Long-term debt | ​ |  | 8,347 | ​ |  | 2 | ​ |  | 1,150 | ​ |  | 1,396 | ​ |  | 5,799 | ​ |
| Operating leases | ​ |  | 450 | ​ |  | 138 | ​ |  | 157 | ​ | ​ | 74 | ​ |  | 81 | ​ |
| Interest\* | ​ |  | 3,644 | ​ |  | 234 | ​ |  | 456 | ​ |  | 418 | ​ |  | 2,536 | ​ |
| Total | ​ | ​ | $ 12,532 | ​ | ​ | $ 382 | ​ | ​ | $ 1,776 | ​ | ​ | $ 1,958 | ​ | ​ | $ 8,416 | ​ |

\* Interest on variable rate debt was calculated using the interest rate at year end 2021.

As of December 31, 2021, our gross liability for uncertain tax positions was $25 million. We are not able to reasonably estimate the amount by which the liability will increase or decrease over an extended period of time or whether a cash settlement of the liability will be required. Therefore, these amounts have been excluded from the schedule of contractual obligations.

We do not have required minimum cash contribution obligations for our qualified pension plans in 2021. We are required to fund certain international pension benefit plans in accordance with local legal requirements. We estimate contributions to be made to our international plans will approximate $49 million in 2022. These amounts have been excluded from the schedule of contractual obligations.

We lease certain sales and administrative office facilities, distribution centers, research and manufacturing facilities and other equipment under longer-term operating leases. Vehicle leases are generally shorter in duration. Vehicle leases have residual value requirements that have historically been satisfied primarily by the proceeds on the sale of the vehicles.

### Market Risk

We enter into contractual arrangements (derivatives) in the ordinary course of business to manage foreign currency exposure and interest rate risks. We do not enter into derivatives for speculative or trading purposes. Our use of derivatives is subject to internal policies that provide guidelines for control, counterparty risk, and ongoing monitoring and reporting, and is designed to reduce the volatility associated with movements in foreign exchange and interest rates on our income statement and cash flows.

We enter into foreign currency forward contracts to hedge certain intercompany financial arrangements, and to hedge against the effect of exchange rate fluctuations on transactions related to cash flows denominated in currencies other than U.S. dollars. We use net investment hedges as hedging instruments to manage risks associated with our investments in foreign operations. As of December 31, 2021, we had a total of €1,150 million senior notes designated as net investment hedges.

We enter into cross-currency swap derivative contracts to hedge certain Euro denominated exposures from our investments in certain of its Euro denominated functional currency subsidiaries. We use net investment hedges as hedging instruments to manage risks associated with our investments in foreign operations. As of December 31, 2021, we had €425 million of cross-currency swap derivative contracts outstanding designated as a net investment hedge.

We manage interest expense using a mix of fixed and floating rate debt. To help manage borrowing costs, we may enter into interest rate swap agreements. Under these arrangements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. As of December 31, 2021, we had $1,250 million of interest rate swaps outstanding.

Refer to Note 9 for further information on our hedging activity.

Based on a sensitivity analysis (assuming a 10% change in market rates) of our foreign exchange and interest rate derivatives and other financial instruments, changes in exchange rates or interest rates would increase/decrease our financial position and liquidity by approximately $278 million. The effect on our results of operations would be substantially offset by the impact of the hedged items.

### GLOBAL ECONOMIC AND POLITICAL ENVIRONMENT

### COVID-19

In March 2020, the COVID-19 was declared a pandemic by the World Health Organization. The COVID-19 pandemic is continuing to affect major economic and financial markets and industries are facing the challenges with the economic conditions resulting from efforts to address the pandemic, including supply shortages, inflation and other challenges, such as those resulting from the introduction of vaccination mandates. While many government restrictions in the U.S. have eased throughout 2021, restrictions on activities continue in many other regions, particularly those where vaccination rates lag, continuing to impact consumer activity in those regions. Concerns remain that our markets could see a resurgence of cases triggering additional government mandated lockdowns or similar restrictions on activity, for example due to the emergence of a variant against which existing vaccines are not as effective or which may be more easily transmitted, particularly to those unvaccinated. These conditions have had and will continue to have a negative impact on market conditions and customer demand throughout the world.

We expect continued, if uneven, global economic recovery. We have also experienced continued substantial delivered product cost inflation. While we expect the challenges that affected us and the rest of the world in the fourth quarter to continue into the first quarter of 2022, assuming the rate of cost inflation and COVID impacts ease progressively in the second half of the year, we believe our continued actions should help us deliver improved results in 2022.

### Global Economies

Approximately half of our sales are outside of the U.S. Our international operations subject us to changes in economic conditions and foreign currency exchange rates as well as political uncertainty in some countries which could impact future operating results.

Argentina has continued to experience negative economic trends, evidenced by multiple periods of increasing inflation rates, devaluation of the Argentine Peso, and increasing borrowing rates. Argentina is classified as a highly inflationary economy in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina. During 2021, sales in Argentina represented less than 1% of our consolidated sales. Assets held in Argentina at the end of 2021 represented less than 1% of our consolidated assets.

In February 2022, the U.S. and the European Union responded to Russia’s invasion of Ukraine by imposing various economic sanctions. The U.S. and other countries could impose wider sanctions or take further actions if the conflict escalates. While it is difficult to anticipate the impact the sanctions may have on Ecolab, any further sanctions imposed or actions taken by the U.S. or other countries, or any retaliatory measures by Russia in response, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations. During 2021, net sales to Russia and Ukraine were approximately 1% of consolidated net sales.

### NEW ACCOUNTING PRONOUNCEMENTS

Information regarding new accounting pronouncements is included in Note 2.

### NON-GAAP FINANCIAL MEASURES

This MD&A includes financial measures that have not been calculated in accordance with U.S. GAAP. These non-GAAP measures include:

- Fixed currency sales
- Adjusted net sales
- Adjusted fixed currency sales
- Acquisition adjusted fixed currency sales
- Adjusted cost of sales
- Adjusted gross margin
- Fixed currency operating income
- Fixed currency operating income margin
- Adjusted operating income
- Adjusted operating income margin
- Adjusted fixed currency operating income
- Adjusted fixed currency operating income margin
- Acquisition adjusted fixed currency operating income
- Acquisition adjusted fixed currency operating income margin
- Adjusted other (income) expense
- Adjusted interest expense, net
- EBITDA
- Adjusted tax rate
- Adjusted net income from discontinued operations, net of tax
- Adjusted net income from continuing operations attributable to Ecolab
- Adjusted diluted EPS from continuing operations

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP adjusted financial measure for net sales excludes Purolite sales. Our non-GAAP adjusted financial measures for cost of sales, gross margin, operating income, other (income) expense and interest expense exclude the impact of special (gains) and charges and (with the exception of other (income) expense) the impact of the Purolite transaction, and our non-GAAP measures for tax rate, net income from continuing operations attributable to Ecolab and diluted EPS from continuing operations further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

EBITDA is defined as the sum of net income including non-controlling interest, provision for income taxes, net interest expense, depreciation and amortization. EBITDA is used in our net debt to EBITDA ratio, which we view as important indicators of the operational and financial health of our organization.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange. Fixed currency amounts included in this Form 10-K are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2021. We also provide our segment results based on public currency rates for international purposes.

Our reportable segments do not include the impact of intangible asset amortization from the Nalco merger or the impact of special (gains) and charges as these are not allocated to the Company’s reportable segments.

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition, exclude the results of our divested businesses from the twelve months prior to divestiture and the Venezuelan results of operations from all comparable periods. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

These non-GAAP measures are not in accordance with, or an alternative to U.S. GAAP, and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the U.S. GAAP measures included in this MD&A and we have provided reconciliations of reported U.S. GAAP amounts to the non-GAAP amounts.

## Market risk

As filed, 172 characters.

The discussion under the heading entitled "Market Risk" and “Global Economic and Political Environment” is incorporated by reference from Part II, Item 7 of this Form 10-K.

## Controls and procedures

As filed, 1,824 characters.

### Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

As of December 31, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended). Based upon that evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are effective.

### Management’s Report on Internal Control Over Financial Reporting

Refer to page 49 of this Annual Report for “Management’s Report on Internal Control Over Financial Reporting.”

### Report of Registered Public Accounting Firm

Refer to page 50 of this Annual Report for the “Report of Independent Registered Public Accounting Firm.”

### Changes in Internal Control Over Financial Reporting.

During the period October 1 - December 31, 2021, other than the Purolite acquisition, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are continuing our implementation of our enterprise resource planning (“ERP”) system upgrades, which are expected to occur in phases over the next several years. These upgrades, which include supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades of the ERP systems will affect the processes that constitute our internal control over financial reporting and will require testing for effectiveness.

Filed Feb 25, 2022.
Source: SEC EDGAR, the filing index for accession 0001558370-22-002059. Last ingested by Listed: Nov 13, 2026, 16:24 ET. No prices; not investment advice.
